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ABSTRACT OF THE DISSERTATION
Sex Differences in Uropathogenic Escherichia coli Urinary Tract Infection
by
Patrick David Olson
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Microbiology and Microbial Pathogenesis
Washington University in St. Louis, 2018
Associate Professor David A. Hunstad, Chair
Urinary tract infections (UTIs) are among the most common bacterial infections which
plague humans. Community-onset UTI is widely viewed as a disease only of women; indeed,
its occurrence between 2 and 60 years of age is almost exclusive to females. However, the
disease also affects substantial male patient populations, namely infants and the very elderly.
While female cases of complicated and upper-tract UTI (pyelonephritis) outnumber male cases
overall, men carry an increased risk of mortality from these infections. Sex differences in UTI
epidemiology have heretofore been attributed almost entirely to anatomic and hygienic factors in
females, including the permissiveness of surrounding environments to microbial colonization,
shorter urethral length, and shorter distance from anus to the urethral meatus. However, these
hypotheses and potential mechanisms driving sex differences in UTI have not been investigated
due to a lack of preclinical models allowing sex comparisons.
In response to this deficit, we devised a minimally invasive surgical bladder inoculation
technique that yields reproducible upper and lower UTI in both male and female mice. Acute
uropathogenic Escherichia coli (UPEC) infection in males of two mouse strains recapitulated the
intracellular bacterial community pathway previously shown in females. Compared with females,
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C3H/HeN males displayed a striking predilection for chronic cystitis, manifesting as persistent
bacteriuria, high-titer bladder bacterial burdens, and chronic inflammation as previously
characterized in catheter-infected C3H/HeN females. Further, males developed more severe
pyelonephritis, as well as nearly 100% penetrant renal abscesses, a complication that is rare in
female mice. Within the abscess, UPEC formed a dense nidus of intratubular, biofilm-like
communities that appeared sheltered from surrounding inflammatory cells by a fibrotic capsule.
The formation of these abscess communities required type 1 pili, a major urovirulence
determinant in the bladder but not previously implicated in pyelonephritis.
Severe ascending UTI in males was sharply abrogated following castration, but
complemented with exogenous testosterone. Similarly, administration of exogenous testosterone
in C3H/HeN females imparted susceptibility to severe pyelonephritis and abscess formation.
Susceptibility to severe UTI was also induced in both sexes with 5-α-dihydrotestosterone or
attenuated by treatment with the antiandrogen flutamide. Further, male mice lacking a functional
androgen receptor were protected from severe upper-tract UTI. Collectively, these data show
that specific activation of the androgen receptor augments severity of UTI in both sexes.
Our mini-surgical model provides a new preclinical platform for translatable studies of UTI
pathogenesis in both male and female hosts, specifically expanding studies of pyelonephritis,
ascending renal abscess development, and the treatment of complicated UTI. The discovery of
intratubular UPEC communities in this model offers a first look at early renal abscess
pathogenesis and helps to explain the need for prolonged antimicrobial treatment during severe
pyelonephritis. Further, our findings suggest that modulation of androgens may represent a
novel therapeutic route to combat recalcitrant or recurrent UTI, and may help to explain why
certain patient populations are more likely to develop UTI.
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CHAPTER ONE
INTRODUCTION TO THE DISSERTATION

Modified from Olson and Hunstad (2016) Sex and other factors influencing urinary tract
infection pathogenesis. In: Bjerklund Johansen TE, Wagenlehner FME, Cho YH, Matsumoto T,
Krieger JN, Shoskes D, Naber KG, eds. Urogenital Infection and Inflammation. Arnhem,
Netherlands: European Association of Urology (in press).

Sex as a biological variable
“From womb to tomb” it matters, argues the 2001 Institute of Medicine report (1); biological
sex should be a fundamental consideration in human health and disease. Indeed, a number of
human diseases manifest profound sex-based differences in prevalence, incidence, severity, and
response to treatment. Yet, sex as a biological variable has long been ignored experimentally in
the biomedical sciences and clinically in the application of evidence-based medicine (2, 3).
Research and medicine in the US and other countries are currently on the verge of a paradigm
shift in which sex should and will increasingly be considered from bench to bedside (2-4).
Such a sex bias is well entrenched in our understanding of urinary tract infections (UTIs),
a collection of diseases which have been both prejudiced and understudied because of their
disproportionate affliction of women and long-standing experimental and clinical sex biases.
UTIs are among the most common bacterial infections that plague humans. On an epidemiologic
basis, community-onset UTI is widely viewed as a disease only of women; indeed, its occurrence
between 2 and 60 years of age is almost exclusive to females, and it is estimated that at least half
of American women will suffer a UTI during their lifetimes (5). However, in certain populations
the incidence of male UTI matches or exceeds that in females; epidemiologic data also suggest a
sex difference in morbidity from upper-tract UTI (6-9). To better understand resistance and
1

susceptibility mechanisms to UTI, it is important that we consider age- and sex-related
discrepancies that are evident in the disease, and how sex and other host factors may influence
the pathogenesis and outcomes of ascending UTI.

Host factors influencing UTI
Though contemporary and emerging technologies will enable further investigation of the
presumed sterility of the urinary tract, microbiologic health of the urinary tract depends on
multiple host factors, including a finely tuned innate inflammatory response, which act to
eliminate potential uropathogens from the bladder and kidneys (10-13). Despite repetitive
exposure of this potentially hospitable, nutrient-rich environment to bacterial pathogens (e.g.,
following sexual intercourse (14)), bacteriuria in the otherwise healthy human host usually is
transient (15-17). Host traits that compromise the defenses of the urinary tract augment disease
susceptibility, severity, and progression. Forward flow of urine provides a formidable
mechanical defense; dysfunctional voiding and other urodynamic abnormalities are clearly
associated with increased susceptibility to UTI in children and adults (18). Such conditions in
the adult female likely include pregnancy, which also predisposes to UTI (19). Factors which
increase the hospitability of the bladder microenvironment to infection, such as glycosuria
associated with diabetes mellitus, likewise increase susceptibility to UTI (20); hyperglycemia
may also additionally compromise the activity of phagocytes. Finally, impairment of the innate
immune response either by immunosuppression or genetic defects in innate components lead to
increased frequency of UTI (12). Multiple efforts to define human genetic variation imparting
susceptibility to UTI have been modestly successful. Attention in this realm has been focused
largely on host innate immune genes. However, it has also become clear that susceptibility is
2

both polygenic and environmental, and that genetic determinants of distinct clinical syndromes
(asymptomatic bacteriuria, cystitis, and pyelonephritis) must be pursued independently.

Sex and UTI
However, the host trait that is most influential in the development of UTI is undeniably
biological sex. The frequency of UTI changes drastically across the lifespan and varies by sex
(21). As mentioned previously, the occurrence of UTI in middle age is almost exclusive to
females. However, certain populations of males show an increased risk of UTI. The sex
discrepancies seen in UTI epidemiology have been traditionally attributed to anatomic (and, less
conclusively, hygienic) factors, including the permissiveness of the surrounding vaginal and
perineal environments to microbial colonization, a shorter distance from the anus to the urethral
meatus, and shorter urethral length in females.
UTI in young children is common (22, 23). The sex ratio in UTI incidence among infants is
approximately 2:1 – still favoring females, but at a much lower ratio than in later childhood and
beyond. In fact, many studies have shown that male UTI cases outnumber females within the
first 3-6 months after birth (24-31). Thereafter, UTI susceptibility wanes in males through later
infancy. Infants and young children thus may represent a unique patient population in which to
investigate sex differences in UTI. Clinically, prompt diagnosis and treatment of UTI in infancy
is necessary to prevent renal scarring and potential long-term complications (32). Interestingly, a
history of maternal UTI during pregnancy has been associated with up to a 5.9-fold higher risk of
UTI in both sexes during infancy (33, 34). It is unclear if this risk arises from inheritance of
genetic predisposition to UTI, intrapartum or postpartum transmission of virulent uropathogens
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from the maternal genitourinary tract to the microbiota of the infant, or other environmental
factors.
Though women represent >90% of UTI patients between early childhood and late middle
age (5, 35, 36), complicated UTI manifests in both sexes across this time frame in patients with
indwelling urinary catheters, diabetes mellitus, spinal cord injuries, immunosuppression, and
structural or urodynamic abnormalities. Notably, while female cases of complicated and uppertract UTI (pyelonephritis) outnumber male cases overall, men carry an increased risk of mortality
from these infections (6-9). Thousands of men, particularly those of advancing age, also suffer
from acute and chronic bacterial prostatitis, a clinical diagnosis with signs, symptoms, and
etiological pathogen profiles that overlap substantially with those of lower UTI in females (37,
38). The incidence of UTI in males increases substantially after 60 years of age, largely because
of abnormal voiding patterns due to acquired urodynamic abnormalities (e.g., benign prostatic
hyperplasia) (5, 21, 39). In total, UTIs comprise debilitating diseases with substantial morbidity
and occasional mortality among males (37, 38).

Pathogenesis of bacterial cystitis
Though a number of distinct bacterial pathogens may cause UTI and prostatitis,
uropathogenic Escherichia coli (UPEC) predominate among etiological agents in both sexes,
causing >80% of community-onset UTI, roughly one fourth of hospital-acquired UTI, and >70%
of infectious prostatitis (5, 21, 40). Our knowledge of the molecular details of UPEC
pathogenesis has been developed largely in an exclusively female murine model. In this widely
used model of bacterial cystitis, female mice are briefly catheterized and uropathogenic bacteria
inoculated into the bladder lumen; however, the bladders of male mice are not reliably accessed
4

by catheter, precluding studies of male cystitis and pyelonephritis using this method. Upon
delivery to the female bladder, UPEC and other uropathogens first encounter the stratified
transitional epithelium, lined by a single layer of large, multinucleated superficial facet cells
apically coated with an array of integral membrane proteins known as uroplakins (41). UPEC
exploit mannose moieties decorating these uroplakins as the receptor for their major virulence
determinant, adhesive type 1 pili (42, 43). UPEC genomes typically contain multiple discrete
loci encoding highly resilient, heteropolymeric pili that are assembled via the canonical
chaperone-usher secretion pathway (44). Absence of type 1 pili or the tip adhesin FimH
abolishes bacterial attachment and subsequent cystitis (45, 46). In a similar way, P pili can bind
globoseries glycolipids found on the renal epithelium (47, 48), potentially accounting for the
predilection of P-piliated E. coli to adhere to kidney tissue and cause pyelonephritis (49).
Following type 1 pilus-mediated attachment to the uroepithelium, UPEC are rapidly
internalized into superficial facet cells (45, 46, 50-65). The FimH adhesin is both necessary and
sufficient for uroepithelial invasion (51, 60, 66). After a single bacterium has invaded a facet
cell, it may then rapidly replicate in the host cell cytoplasm, initially forming loose collections
that subsequently coalesce into densely packed intracellular bacterial communities (IBCs) (55).
Infected bladder epithelial cells may be exfoliated, eliminating some IBCs in the urine (67, 68);
meanwhile, a subset of UPEC may flux from the mature IBC, assume a filamentous morphology
that resists neutrophil phagocytosis, and initiate further rounds of IBC formation by invading
nearby naive epithelial cells (69, 70). Murine and in vitro evidence for this IBC cascade has
been corroborated by detection of shed IBCs in female human urines (71, 72), suggesting that the
murine IBC pathway recapitulates acute cystitis in women.
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There are two phenotypic outcomes of murine cystitis, which are dependent on the host
genetic background used. Following resolution of acute infection in typical model hosts (e.g.,
C57BL/6 females), UPEC may establish a quiescent intracellular reservoir (QIR) within the
bladder epithelium that resists systemic antibiotic therapy and is also protected from host
immune mechanisms (45, 73). Such a reservoir can persist for months, during which the urine is
sterile, with occasional “spikes” of cultivatable E. coli. However, UPEC are readily recovered
from bladder tissue up to 4 months later (74), and there is no histologic evidence of inflammation
in these chronically colonized tissues (45). Consequently, QIRs are believed to represent seeds
for same-strain recurrent UTI. In susceptible murine hosts (e.g., C3H/HeN), a fraction of mice
are unable to resolve acute UTI, developing long-term chronic bacterial cystitis with ongoing
high tissue bacterial burden and inflammation (75). By 2 weeks post-infection (wpi), C3H/HeN
females show a bimodal phenotype, with an inoculum-dependent fraction of mice developing
chronic cystitis while remaining mice resolve infection to the QIR state. The nature and
amplitude of the immune response within the first 24 hours of infection may influence the fate of
individual C3H females (75).
While our knowledge of the UPEC intracellular cascade and murine infection outcomes
has increased exponentially, studies have been completed entirely in females. Thus, it has been
unclear how the IBC pathogenic cascade proceeds during male cystitis and if there are
differences in murine infection outcome. Likewise, we know relatively little about the
pathogenic mechanisms for ascending bacterial infection of the kidney in comparison to our
understanding of the intracellular cascade used during bacterial cystitis. Female mice are largely
resistant to ascending pyelonephritis in the catheterization model (75). Consequently, our
knowledge of the virulence repertoire required by uropathogens, mechanisms for bacterial
6

persistence and propagation, and host response to infection within the kidney are incompletely
defined.

Male UTI
Unfortunately, the epidemiology, diagnosis, and treatment of UTI in male populations
have been poorly described compared to the robustly studied female populations, although
substantial differences exist between them (76). Infections of male accessory organs, including
prostatitis, epididymitis, orchitis, and seminal vesiculitis, can also be classified as exclusively
male forms of UTI. UTI in adult male patients is often viewed as “complicated,” because these
organs are sometimes involved and due to the relative paucity of cases in men compared to
women.
Males also exhibit an increase in some specific risk factors that potentiate UTI. A lack of
circumcision increases risk for UTI in both infants (77-79) and adult men (80). Men have a
striking predilection for spinal cord injury, outnumbering female cases four to one; chronic,
recurrent UTIs present a difficult and often lifelong challenge in patients with neurogenic
bladder arising from such injuries and other causes (81). Complicated UTI also manifests in
hospitalized males with indwelling urinary catheters, those receiving immunosuppression, and
those with structural abnormalities (particularly in infancy).
Optimal treatment regimens (antibiotic choice and duration) for uncomplicated UTI in
females have been the subject of numerous clinical trials, and the contemporary clinician can
rely on published guidelines for these patients (82), while evidence supporting proper choice of
antimicrobial agents and duration of therapy for men is less clear. Many expert
recommendations call for extended (14 days or longer) courses of antibiotic therapy to treat male
7

UTI (39, 83-85). However, a recent study found no differences in acute resolution or recurrence
rate between male UTI patients treated for < 7 days versus those treated for > 7 days; moreover,
longer-duration therapy was associated with the subsequent development of Clostridium difficile
infection (86). Ongoing studies and clinical trials are expected to inform the development of
more evidence-based and specific recommendations for treating male UTI (87).

Hormones and UTI
Developing evidence suggests that hormonal milieu may impact UTI susceptibility and
severity. Our increasing knowledge of this field is particularly interesting as it may ultimately
inform approaches that represent alternatives to antibiotic treatment.
There are extensive but somewhat conflicting data on the influence of estrogen on
susceptibility to UTI. Young adult women, who exhibit the highest estrogen levels, account for
the majority of community-onset UTI cases, and high estrogen levels have been linked to
increased UTI susceptibility (88). However, post-menopausal females also experience an
increased incidence of UTI, which in some cases has been treated with estrogen
supplementation. Results from murine studies employing ovariectomized and/or estrogensupplemented females to examine the influences of estradiol on UTI pathogenesis are likewise
conflicting. Some studies have found modest increases in bladder bacterial burdens in estrogendepleted hosts, particularly during the acute phase of cystitis (89, 90). Conversely, Curran et al.
noted an increased risk of upper-tract UTI in mice following estrogen treatment (91). These
experimental models notably bypass the vaginal and periurethral microenvironment, as mice are
inoculated by transurethral catheterization of the bladder. Collectively, the available data
suggest that the impact of estrogen on bacterial pathogenesis within the urinary tract proper is
8

likely minor. However, many have posited that estrogens may influence periurethral
colonization by uropathogens and alter UTI-relevant facets of the vaginal environment (e.g.,
composition of the vaginal microbiome, dryness, sexual intercourse frequency). In line with this
hypothesis, a Cochrane review concluded that topical estrogens show possible benefit in
reducing UTI risk, albeit with a number of side effects (92). Of note, recent evidence suggests
that high estradiol levels may cause opposing changes in both bladder fortification and
receptivity to infection, providing a viable hypothesis for inconsistent estrogenic influences on
UTI. High estradiol levels may induce expression of major adhesive receptors for uropathogens
in bladder epithelial cells in vitro (thereby promoting increased bacterial adherence and
invasion), while a protective effect may be attributable to its ability to induce antimicrobial
peptides during acute UTI (90). The influence of other hormones in the hypothalamic-pituitarygonadal axis, including testosterone, on UTI susceptibility has not been explored.

Summary
Men and women display fundamental differences in their susceptibility to infectious diseases.
These dissimilarities may stem from a multitude of differences: in pathogen exposure, cultural
and behavioral issues, anatomy, hormonal expression, treatment efficacy, socio-economic
influences, and many more. Most notably, sex differences in immunity have been clearly
described, with females displaying enhanced resistance to many infections because of more
robust immune responses controlling pathogens (93-95). This enhanced defense in women has
been hypothesized to have evolved from the need to protect their fetuses from infection (96), and
is associated with the greater frequency and severity in women of many chronic inflammatory
and autoimmune diseases (97, 98).
9

Ascending UTI represents a contradiction to this paradigm, being one of the few
infectious diseases which disproportionately afflicts females over males. In considering how
biological sex influences UTI, the hypothesized protective mechanism for males is anatomy,
while repeated introduction of bacterial pathogens to the urinary tract in females necessitates a
finely tuned innate surveillance and defense system as primary protection. Traits or
interventions which bypass or hamper these defenses in females represent risk factors for chronic
and/or recurrent UTI (13). Sex differences in UTI epidemiology have heretofore been attributed
almost entirely to anatomic and hygienic factors, including the permissiveness of vaginal and
perineal environments to microbial colonization, shorter urethral length, and shorter distance
from anus to the urethral meatus in females (14, 21, 99). However, these hypotheses have not
been stringently proven, and substantial deficiencies persist in our understanding of the interplay
between host sex and uropathogens.
There have been recent calls by the US National Institutes of Health (4) and in the basic
and clinical literature (2, 100, 101) for sex-based research approaches to infectious and other
diseases, including a specific focus on UTI (86, 102). A greater understanding of how biological
sex influences UTI promises to inform the development of novel therapeutics and interventions,
yielding better sex-based treatment and prevention strategies for the benefit of all patients.
Substantial data from the current murine model and female patients suggest that the IBC
represents a protected replicative niche, necessary for the establishment and progression of UTI
in female hosts. However, this emerging paradigm has not been extended to male hosts, and sex
influences on the intracellular pathogenic cascade may underlie the observed sex discrepancies in
UTI in human patients. Technical barriers to infecting male mice have heretofore precluded the
extensive study of male UTI in model hosts, resulting in a tremendous knowledge gap regarding
10

host and microbial mechanisms underlying sex discrepancies in this disease. This body of work
sought to address this gap by developing an innovative minimally-invasive surgical technique
that bypasses simple anatomic differences to permit infection of the urinary tract in male and
female model hosts. This significant advance allowed us to explore the central hypothesis that
intrinsic sex differences in epithelial receptivity and/or immune responses of the urinary tract
underlie phenotypic sex differences in susceptibility to these infections. The new model also
emerged as a novel platform for modeling the pathogenesis and sequelae of severe pyelonephritis
with ascending abscess formation in male mice.
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Abstract
Urinary tract infections (UTIs) occur predominantly in females but also affect substantial
male patient populations; indeed, morbidity in complicated UTI is higher in men. Because of
technical obstacles, preclinical modeling of UTI in male mice has been limited. We devised a
mini-surgical bladder inoculation technique that yields reproducible upper and lower UTI in both
male and female mice, enabling studies of sex differences in these infections. Acute
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uropathogenic Escherichia coli cystitis in males of two mouse strains recapitulated the
intracellular bacterial community pathway previously shown in females. However, surgically
infected C57BL/6 and C3H/HeN females exhibited more robust bladder cytokine responses and
more efficient UPEC control than males. Compared with females, C3H/HeN males displayed a
striking predilection for chronic cystitis, manifesting as persistent bacteriuria, high titer bladder
bacterial burdens, and chronic inflammation. Further, males developed more severe
pyelonephritis, as well as 100% penetrant renal abscess (a complication that is rare in female
mice). These phenotypes were sharply abrogated following castration, but complemented with
exogenous testosterone, suggesting that male susceptibility to UTI is strongly influenced by
androgen exposure. These data substantiate the long-standing presumption that anatomic
differences in urogenital anatomy confer protection from UTI in men; however, as observed
clinically, male sex was associated with more severe UTI once these traditional anatomic barriers
were bypassed. This study introduces a highly tractable preclinical model for interrogating sex
differences in UTI susceptibility and pathogenesis, and illuminates a more complex interplay
between host sex and UTI than previously appreciated.

Introduction
Community-onset urinary tract infection (UTI) disproportionally afflicts women (1);
however, routine and complicated UTIs in male patients are neither nonexistent nor benign.
Males at the extremes of age, namely infants and the very elderly, exhibit increased incidence of
UTI. Further, complicated UTI commonly manifests in males with urodynamic problems (e.g.,
spinal cord injury, neurogenic bladder), indwelling urinary catheters, immunosuppression, and/or
structural abnormalities. Importantly, while female cases of complicated and upper-tract UTI
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(pyelonephritis) outnumber male cases overall, men carry an increased risk of mortality from
these infections (2-5). Millions of men also suffer from acute and chronic bacterial prostatitis.
In total, UTIs comprise debilitating diseases with substantial morbidity and appreciable mortality
specific to males (6, 7). Of note, uropathogenic Escherichia coli (UPEC) is the predominant
cause of UTI in both sexes, causing >80% of community-onset UTI, ~25% of hospital-acquired
UTI, and >70% of infectious prostatitis (1, 8-10).
Sex differences in UTI epidemiology have heretofore been attributed almost entirely to
anatomic and hygienic factors, including the permissiveness of vaginal and perineal
environments to microbial colonization, shorter urethral length, and shorter distance from anus to
the urethral meatus in females (9, 11, 12). However, these hypotheses have not been stringently
proven, and substantial deficiencies persist in our understanding of the interplay between host
sex and uropathogens. Recent advances in our translational view of UTIs and in the molecular
details of UPEC pathogenesis have been developed in an exclusively female murine model
where pathogens are delivered into the bladder lumen by transurethral catheterization (13, 14).
however, the bladders of male mice cannot be reliably catheterized. Upon delivery to the female
bladder, UPEC are rapidly internalized into superficial facet cells lining the stratified transitional
epithelium (15-26), subsequently replicating in the cytoplasm to form biofilm-like masses of
bacteria termed intracellular bacterial communities (IBCs) (21). Murine evidence for this IBC
cascade has been corroborated by detection of exfoliated IBCs in the urine of women and girls
with cystitis (27, 28). Female mice either resolve acute cystitis or develop chronic bacterial
cystitis, while very few develop lasting kidney infection or renal abscess (29, 30). While chronic
cystitis as described in murine hosts may not be common clinically with routine antibiotic

25

treatment, increasing evidence suggests this to be a relevant model for severe and recurrent UTI
(31, 32).
Previous studies have instilled uropathogens into the urethra of male mice (33, 34),
inducing infection of the prostate but failing to reproducibly infect the bladders and kidneys.
The lack of a tractable male model of UTI has precluded detailed examination of host and
microbial mechanisms underlying the sex discrepancies observed in UTI. In response to this
deficit, we developed a mini-surgical technique that bypasses simple anatomic sex differences to
permit infection of the urinary tract in both male and female mice. Acute cystitis utilized an IBC
pathway in males which mirrored acute bladder infection in females. While most surgically
infected female mice controlled UPEC effectively, males exhibited a sharply higher prevalence
of chronic cystitis. More striking, male mice exhibited marked susceptibility to renal abscess
and pyelonephritis, mirroring the increased morbidity reported in men who develop these
complicated UTIs. These male UTI phenotypes were reversed by gonadectomy but
complemented via exogenous testosterone administration, implicating androgens in susceptibility
to severe UTI. Collectively, this study illuminates sex-based influences on susceptibility and
host response to UTI and establishes a novel platform for modeling the pathogenesis and
sequelae of cystitis, pyelonephritis, and ascending renal abscesses.

Materials and methods
Bacterial strains and growth conditions.
Uropathogenic E. coli strain UTI89 was isolated from a patient with cystitis (35). UPEC
strain CFT073 was isolated from the blood of a patient with acute pyelonephritis (36). For
surgical infections, bacteria were grown statically in Luria-Bertani (LB) broth for 16 h at 37°C to
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induce type 1 piliation. The cultures were centrifuged at 7,500 × g for 10 min at 4°C before
resuspension in sterile phosphate-buffered saline (PBS) to a final density of ~4 × 108 CFU/ml.

Surgical murine model of UTI.
Animal care and use protocols received prior approval from the Washington University
Animal Studies Committee. Experiments were conducted in inbred C57BL/6 (Jackson
Laboratories, Bar Harbor, ME) or C3H/HeN (Harlan Laboratories, Indianapolis, IN) murine
backgrounds. Mice were housed under constant temperature and humidity, with a 12-h
light/dark cycle. The female murine model of cystitis with transurethral inoculation via catheter
has been described in methodologic detail (13, 37). For mini-surgical infection, mice aged 8-9
weeks were maintained under inhalation anesthesia with 3% isoflurane via vaporizer and nose
cone. Anesthetized mice were positioned supine, and the ventral abdomen was shaved and
disinfected with 70% alcohol and 2% chlorhexidine solution. A 2-3 mm, vertical, midline
incision was made directly overlying the bladder, first through the abdominal skin and then the
peritoneum. The bladder was exposed through the incision using gentle bilateral pressure on the
abdomen and aseptically emptied. The inoculum was prepared in a 1-mL tuberculin syringe
adapted to a 30-gauge, 0.5-inch needle. The needle was introduced to the bladder lumen near the
neck of the bladder at a 45-degree angle. The lumen was inoculated with 50 μL of bacterial
suspension (containing 1-2 × 107 CFU) over a period of 10 s. The bladder was allowed to
expand for an additional 10 s before withdrawing the needle; the injection site sealed
immediately with no evident leakage. The bladder was gently replaced, the peritoneum and skin
were closed separately with simple, interrupted sutures, and the animal was awakened in fresh
air. Infections were allowed to proceed for durations from 6 h to 4 weeks.
27

Determination of urine and tissue bacterial loads.
Post-infection clean-catch urine samples were collected using gentle suprapubic pressure,
serially diluted and plated to LB agar to enumerate CFU. For organ titers, mice were euthanized
by CO2 asphyxiation, and bladders and kidney pairs were aseptically removed, homogenized in 1
ml or 0.8 ml (respectively) of sterile PBS, and serially diluted and plated. Cystitis in C3H/HeN
mice was termed “chronic” if endpoint bladder and all urine titers were >104 CFU/ml, and
“resolved” if endpoint bladder burdens or at least one urine titer were <104 CFU/ml (29, 30, 32).

Tissue and serum cytokine analysis.
The concentrations of 23 mouse cytokines in whole-bladder homogenates or sera were
analyzed with a multiplex bead array platform (Bio-Plex; Bio-Rad, Hercules, CA) as described
previously (29, 38). Data represent the mean and standard deviation from five individual mice
across 2 biological replicates per time point, each analyzed in technical duplicate.

IBC enumeration and confocal microscopy.
For IBC quantification, bladders were bisected, splayed, fixed, and stained for bacterial
β-galactosidase as previously described (39). IBCs were counted under a dissecting light
microscope. For IBC confocal microscopy, splayed bladders of C57BL/6 male and female mice
were examined at 16 hpi with GFP-expressing UTI89, as described previously (39). Bacteria
present at chronic time points were visualized by immunofluorescence. Splayed bladder halves
were fixed in 2.5% paraformaldehyde, blocked in 1% BSA, 0.3% Triton X-100 in PBS for 1 h,
incubated with rabbit anti-E. coli (E3500-06C, US Biological, Salem, MA) and secondary
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AlexaFluor 488-conjugated goat anti-rabbit IgG (Life Technologies, Grand Island, NY)
antibodies, and stained with SYTO 61 red fluorescent nucleic acid stain (Molecular Probes,
Eugene, OR). Images were acquired on a Zeiss LSM 510 META confocal laser scanning
microscope (Carl Zeiss Inc., Thornwood, NY).

Ex vivo gentamicin protection assay.
Quantification of intracellular and extracellular bacteria in the murine bladder 6 hpi was
performed by a modified ex vivo gentamicin protection assay, as previously described (40).
Bladders were aseptically harvested at 6 hpi, bisected, and washed vigorously in PBS, which was
plated to enumerate extracellular bacteria. Following 90 min incubation at 37°C in PBS
containing gentamicin (100 µg/ml), bladders were washed with PBS, then homogenized and
plated for intracellular CFU.

Bladder and kidney histopathology.
Bladder and kidneys were bisected and fixed in methacarn (60% methanol, 30%
chloroform, 10% glacial acetic acid). Fixed tissues were embedded in paraffin, sectioned, and
stained with hematoxylin and eosin or Gomori trichrome stain.

Serum collection and storage.
Venous blood was collected by submandibular puncture using 5-mm steel lancets (MediPoint,
Mineola, NY) into Microtainer serum separation tubes (Becton Dickinson, Franklin Lakes, NJ).
Samples were allowed to clot for 1 h and were clarified by centrifugation at 15,000 × g for 5 min
before storage at -80°C.
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Gonadectomy and testosterone implantation.
Bilateral orchiectomy (castration), bilateral ovariectomy, or sham operations were
performed at Harlan Laboratories (Indianapolis, IN) following standard procedures at 5 weeks of
age. Animals were allowed to recover 1 week before shipment. Where indicated, 60-day
continuous release pellets containing 25 mg testosterone or placebo (Innovative Research of
America, Sarasota, FL) were implanted subcutaneously at the nape of the neck 5 days following
castration or sham operation. Mice were surgically infected at 9 weeks of age (i.e., 4 weeks
following gonadectomy or sham surgery).

Statistics.
Statistical tests for significance were performed using Prism 6 software (GraphPad, La
Jolla, CA). Observed differences in bacterial CFU, IBC numbers, and cytokine levels were
analyzed with the unpaired, two-tailed, nonparametric Mann-Whitney U test. To compare
proportions of mice developing persistent bacteriuria and chronic cystitis or renal abscess, a twotailed Fisher’s Exact test was used. P values < 0.05 were deemed significant.

Results
Direct bladder inoculation reliably infects the urinary tract of C57BL/6 mice.
We developed a highly reproducible, minimally invasive surgical approach that allows
direct male-female comparisons in UTI pathogenesis. We first employed our mini-surgical
inoculation model to induce UTI in C57BL/6 male and female mice with the cystitis-derived
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UPEC strain UTI89, monitoring bladder and kidney colonization at three time points
representing acute and chronic stages of UTI (29, 30, 41) (Figure 1). Organ titers in surgically
infected female C57BL/6 were similar to published bacterial burdens in catheter-infected
females (22, 29, 42-44), indicating that our mini-surgical method recapitulates the widely used
female model (13). Mice displayed no signs of systemic infection or peritonitis, and blood
cultures were sterile 6 and 24 hours post infection (hpi).
Bladder bacterial burdens in C57BL/6 males and females were equivalent at all time
points examined (Figure 1A). However, C57BL/6 males developed significantly higher kidney
titers 24 hpi (P=0.0038) and 2 wpi (P=0.0028) compared to females (Figure 1B). Male and
female C57BL/6 mice expressed similar levels of bladder cytokines and chemokines 6 hpi. By
24 hpi, females displayed modest but statistically significant increases in bladder IL-1α, IL-10,
IL-12 (p40), G-CSF, MIP-1α, and TNF-α content relative to males (Figure 2).

Cystitis in male C57BL/6 mice follows the IBC pathway.
The importance of the IBC pathway in cystitis has not been interrogated in male hosts.
By LacZ staining (39), IBCs were observed in all infected bladders of both sexes, with no
significant differences in IBC number between males and females 6 or 24 hpi (Figure 3A).
Confocal microscopy revealed no differences in bacterial morphology, size, or structure in early
or mature IBCs between sexes (Figure 3B). Thus, acute cystitis in male hosts proceeds through
an IBC pathway analogous to that previously observed in females.
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UPEC more effectively colonize the male C3H/HeN bladder.
We next applied our mini-surgical method in C3H/HeN mice (a host strain in which a
minority of infected females develop chronic cystitis (29)). Surgically infected male C3H/HeN
developed robust acute cystitis, with bladder bacterial loads significantly higher than those in
females 6 hpi (P=0.0003; Figure 4A). Using an ex vivo gentamicin protection assay (40), we
found modest increases in both the intracellular and extracellular bladder compartments of
C3H/HeN males compared to females (Figure 4B). As in the C57BL/6 background, we
observed no differences between sexes in IBC numbers in C3H/HeN hosts 6 or 24 hpi (Figure
4C). We found only modest sex differences in bladder cytokine content during acute cystitis in
the C3H/HeN background (Figure 5).

Male C3H/HeN mice are highly susceptible to chronic cystitis.
In catheter-infected C3H/HeN females, a bimodal distribution of bladder UPEC titers
develops by 2-4 wpi; a minority (20-40%) exhibit chronic cystitis while most females resolve
bacteriuria (29, 39). As previously defined, chronic cystitis comprises persistent, high-titer
bacteriuria (>104 CFU/mL), high bladder bacterial load 2-4 wpi, ongoing robust inflammation,
and persistent inability of the bladder to regenerate the terminally differentiated superficial facet
cell layer (29, 30). Elevation in serum IL-5, IL-6, G-CSF, and KC (CXCL1) 24 hpi constitutes a
biomarker signature that predicts development of chronic cystitis in female mice (29).
C3H/HeN females surgically infected with 107 CFU UTI89 exhibited a phenotypic split
as seen in the catheterization model, with 20% of females showing high bladder CFU 2 wpi
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(Figure 4A). Strikingly, male bladders demonstrated significantly higher bacterial burdens than
females 2 wpi (P<0.001; Figure 4A), with 100% of males developing the high titers typical of
chronic cystitis (P<0.0001 vs. female proportion).
To confirm that these high bacterial loads in male bladders indeed reflected the chronic
cystitis phenotype, we surgically infected male and female C3H/HeN mice and enumerated
bacterial CFU in weekly urine samples and bladder homogenates 4 wpi. Consistent with prior
studies (29, 39, 45) and our initial 2-wpi data (Figure 4A), a minority (24%) of C3H/HeN
females exhibited persistent bacteriuria 4 wpi, compared with 76% of males (P=0.0053 vs.
female proportion; Figures 6A and B). Histopathological analysis of bladders from female or
male mice with persistent bacteriuria demonstrated a hyperplastic transitional cell layer with
complete exfoliation of superficial facet cells, severe edema, and chronic, follicle-like
inflammatory infiltrates in the submucosa (Figures 6C and D). Bladders from male or female
mice that resolved bacteriuria lacked any notable pathology 4 wpi (data not shown). Bladders of
male and female mice with persistent bacteriuria 2 wpi displayed identical bacterial morphology
and luminal colonization by immunofluorescence and confocal microscopy (Figure 7). Both
male and female C3H/HeN with chronic cystitis showed local elevations in multiple proinflammatory cytokines, compared with mice that resolved acute infection (Figure 8). Taken
together, these data argue that the phenotype observed in high-titer male bladders indeed reflects
chronic cystitis as observed in females (29), although male sex is associated with an increased
frequency of developing chronic cystitis.
Surgically infected females that developed chronic cystitis demonstrated inflammatory
cytokine signatures 24 hpi (i.e., elevated IL-5, IL-6, G-CSF, and KC) comparable to those
reported in catheter-infected females (29) (Figure 9). Males demonstrating persistent bacteriuria
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had significantly higher serum IL-6 24 hpi compared with resolved males (P=0.0316); increases
in serum IL-5, G-CSF, and KC trended similarly (Figure 9). These findings suggest that male
C3H/HeN hosts, like females, feature an acute inflammatory checkpoint that influences chronic
infection outcome.

Male C3H/HeN mice develop severe pyelonephritis and renal abscess.
We hypothesized that the amplified renal infection observed in C57BL/6 males (Figure
1B) would be recapitulated more strongly in the C3H/HeN background, a host with increased
propensity for vesicoureteral reflux (43, 46). Indeed, surgically infected male C3H/HeN
displayed significantly higher renal bacterial loads compared to females (P<0.0001; Figure
10A). Moreover, while females largely resolved kidney infection over time, renal bacterial loads
in males rose substantially from 6 hpi to 2 wpi, with no males able to resolve kidney infection
(Figure 10A). These excessive bacterial loads in males correlated with grossly evident renal
abscess 2 wpi (Figure 10B); 100% of males demonstrated gross abscess formation in at least one
kidney, with most (87%) harboring bilateral abscess. In contrast, only 7% of females developed
unilateral abscess (P<0.0001 vs. female proportion). Males surgically infected with UPEC
urosepsis isolate CFT073 likewise exhibited abscess and significantly higher kidney bacterial
titers 2 wpi than females (P=0.0002; Figure 11).
Histologic examination of male C3H/HeN kidneys demonstrated extensive abscess
formation in subcapsular, cortical, and medullary locations (Figure 12). These abscesses
featured a dense neutrophilic infiltrate with areas of necrosis (Figure 10C). The surrounding
renal parenchyma was abnormal throughout, exhibiting interstitial infiltrates, edema and fibrosis,
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mesangial sclerosis, and tubular atrophy with visible thyroidization suggesting active,
progressive renal disease (Figure 10D; Figure 12).

Testosterone mediates UTI severity in male C3H/HeN mice.
The observed susceptibility of male mice to chronic cystitis, pyelonephritis and renal
abscess could be attributable to a number of sex-specific factors. We adapted our model to
examine the potential influences of sex steroid hormones. Females and males were
gonadectomized or sham-operated at 5 weeks of age and allowed to recover completely over 4
weeks before mini-surgical UTI was introduced. We found no observable differences in bladder
or kidney colonization 2 wpi between ovariectomized and sham-operated C3H/HeN females,
suggesting that estrogens do not influence chronic cystitis risk (Figure 13A). However, bladder
bacterial burdens in castrated males 2 wpi were significantly lower than in sham-operated
controls (P=0.0049; Figure 13B). The majority (87%) of sham-operated C3H/HeN males
developed chronic cystitis, compared with only 27% of castrated males (P=0.0025 vs. castrated
proportion). Further, castrated males exhibited a bimodal distribution remarkably similar to
C3H/HeN females. Castration similarly attenuated renal infection, reflected in significantly
lower kidney bacterial titers in castrated animals compared to sham-operated controls (P<0.0001;
Figure 13B).
To specify whether male susceptibility to severe UTI is mediated by androgens or by
another testicular factor, we implanted slow-release testosterone or placebo pellets 5 days after
castration or sham operation. Consistent with above results, castration attenuated severe UTI in
placebo-treated males (Figure 13C). However, treatment of castrated males with exogenous
testosterone reversed the protective effects of gonadectomy; significantly higher bladder
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(P<0.0001) and kidney (P=0.0002) bacterial burdens were present in testosterone-treated
castrated males compared to placebo-treated castrated males (Figure 13C). Testosteronecomplemented castrated males were statistically indistinguishable from placebo-treated sham
males. Collectively, these data indicate that androgens mediate male susceptibility to chronic
cystitis and severe pyelonephritis.

Discussion
In this study, we report the first preclinical UTI model to permit direct elucidation of sex
differences in susceptibility and host response to infection, using a novel inoculation technique
that bypasses anatomic differences in the lower urinary tracts of male and female mice. Acute
cystitis in male mice proceeded through the IBC cascade in a fashion similar to females, but the
incidence of chronic cystitis was strikingly higher in C3H/HeN males. Further, these males
developed more advanced pyelonephritis and highly prevalent abscess formation compared to
females. These phenotypes were mitigated in males who underwent gonadectomy prior to
infection, but complemented with exogenous testosterone. Our findings indicate that sex
influences on susceptibility to multiple forms of UTI are complex and not limited to traditionally
cited anatomic differences. In addition, our mini-surgical model provides a new preclinical
platform for translatable studies of upper- and lower-tract UTI pathogenesis in both male and
female hosts.
To successfully colonize the urinary tract, UPEC must circumvent formidable host defenses,
which are mechanical, biochemical, and immunologic in nature. In ascending UTI, UPEC
evades these defenses, in part, by following a well-documented pathogenic cascade keyed by the
formation of IBCs in the bladder (15-21, 23-26). Our data offer the first evidence of the IBC
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pathway in males and indicate that the events comprising acute cystitis are fundamentally similar
in both sexes. Males that resolved acute infection also maintained a small population of
persisting UPEC within bladder tissue, likely representing the quiescent intracellular reservoirs
believed to seed same-strain recurrent infection in females (42).
Male C3H/HeN mice also showed greater susceptibility to chronic cystitis than females,
with chronically infected animals of both sexes displaying similar histopathology and
inflammatory profiles. The chronic cystitis phenotype has proven to be an important outcome in
female models investigating the natural history of UTI and host responses to repeated UPEC
inoculation (29, 30, 41). Our data support previous research in catheter-infected female mice
demonstrating that infection outcome is determined within 24 hpi via an acute host inflammatory
checkpoint (29). Thus, in both female and male hosts, the nature and degree of early host
inflammatory responses may specify risk for severe or recurrent UTI.
Sex differences in immune response have been demonstrated in a number of human
infections and animal models; in many of these studies, females display more robust resistance to
pathogens (47-49). Among other hypotheses, this enhanced defense has been attributed to an
evolutionary need for pregnant females to protect their fetuses from infection (50) and has been
linked to women’s higher incidence of autoimmune and chronic inflammatory diseases (51, 52).
Germane to the present study, UTI are the most common bacterial infections of women(9) and
females of other animal species (53-55), and UPEC strains isolated from women or female
animals share considerable phylogenetic similarity and parallel virulence profiles (54, 55).
Heightened defenses in the female urinary tract may thus have evolved in response to continual
exposure to bacterial pathogens (e.g., following sexual intercourse (11)). Consistent with this
paradigm, female mice more aptly controlled both lower and upper UTI compared to males in
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our model. Additionally, females displayed higher local proinflammatory cytokines 24 hpi
(when bladder UPEC burdens were similar between sexes), suggesting that a more pronounced
acute inflammatory response may be raised in the female urinary tract to better control infection.
In addition to potential evolutionary pressure to repel urinary pathogens, some evidence
has suggested that estrogen may impact immune response to UTI, although the influence of male
androgens on UTI outcome has not been explored. The incidence of UTI in women increases
following menopause (56), and studies in ovariectomized C57BL/6 mice suggest that diminished
estrogen may favor bacterial persistence in the bladder (57, 58). Here, we found that
ovariectomy did not affect chronic infection outcome in C3H/HeN females, but androgens
potentiated the development of chronic cystitis and severe pyelonephritis in males. The exact
organizational or activational influences of androgens on UTI severity in both males and females
represent areas of ongoing investigation. Notably, our findings suggest that clinical modulation
of androgens may represent a potential therapeutic route to combat recalcitrant or recurrent UTI.
At a glance, our findings in this new model may appear to represent a stark contradiction
to the female predominance in human UTI epidemiology. However, mini-surgical inoculation
bypasses anatomic sex differences below the bladder. Thus, our data are in fact consistent with
the long-standing presumption that UTI risk in women is potentiated by anatomic features.
Conversely, anatomy represents a key defense against UTI in males, and the evolutionarily
“naïve” urinary tract of males may provide a more hospitable environment for UPEC and other
uropathogens once these male anatomic barriers are bypassed. This paradigm is consonant with
clinical data reflecting increased morbidity and mortality in men who develop pyelonephritis and
complicated UTI, compared to women with these conditions (2-5). While acute cystitis was
equivalent in males and female mice, chronic cystitis progression was much higher in males and
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associated with marked renal infection, leading us to speculate that severe UTI in the male
mouse is driven primarily by testosterone-induced susceptibility within the kidney.
In addition to facilitating the study of sex differences, our mini-surgical model fills
another substantial gap in the basic investigation of UTI. No published approaches in
experimental UTI result in more than a very small minority of wild-type animals developing
ascending renal abscess (29, 59, 60). Consequently, the field has lacked ability to model
ascending abscess development and the resolution of severe renal infection with treatment. In
the present model, most C3H/HeN males develop severe pyelonephritis and exhibit renal
abscesses, judged to arise via the ascending route (rather than hematogenous, as we detected no
bacteria in blood cultures). As noted above, C3H mice feature enhanced vesicoureteral reflux
compared to C57BL/6 mice (43, 46), reflecting a risk factor for pyelonephritis that is also
commonly present in the human population. Our work therefore opens a new avenue into
modeling the development, therapy, resolution, and sequelae of severe pyelonephritis and
ascending renal abscess. Beyond these niches, our method also induces visible infection of the
prostate, making the model potentially useful for the study of bacterial prostatitis.
In summary, the work described here will accelerate fundamental investigation into the
mechanisms of UTI initiation, progression, and persistence in male hosts, as well as expanding
studies of pyelonephritis, ascending renal abscess, and the treatment of complicated UTI. These
advances also represent a timely response to recent calls by the National Institutes of Health (61)
and in the basic and clinical literature (62-64) for sex-based research approaches to infectious
and other diseases, including a specific focus on UTI (65, 66). Continued work in this model
promises to address these initiatives at a mechanistic level and to generate translatable advances
in prevention and treatment of these common infections.
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Figures

Figure 1. Direct bladder inoculation reliably infects the urinary tract of C57BL/6 mice.
Female (●) or male (○) C57BL/6 mice were surgically infected with 107 CFU UTI89. (A)
Bladders were homogenized at the indicated time points, serially diluted, and CFU enumerated.
Each point represents one mouse; bars indicate geometric mean. Data comprise three
independent experiments of 5 mice per group. Dotted line represents the limit of detection. (B)
Total bacteria present in both kidneys were enumerated. Aggregate data from three independent
experiments with 5 mice per group are shown. Statistically significant differences between sexes
are indicated (** P < 0.01).
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Figure 2. Male and female C57BL/6 hosts exhibit differences in bladder cytokine
expression 24 hpi. Female (●) and male (○) C57BL/6 mice were surgically infected with UTI89
or mock-infected (harvested 24 hpi) with PBS. Bladders were homogenized 6 hpi, 24 hpi, or 2
wpi and centrifuged to remove cellular debris before cytokine content was measured. Bladder
UPEC burdens were statistically similar between sexes at all time points. Bars represent the
mean from 5 individual mice per time point selected from 2 independent experiments. Samples
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were assayed in duplicate. Statistically significant differences between sexes are indicated (* P
< 0.05; ** P < 0.01).
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Figure 3. Cystitis in male C57BL/6 mice follows the IBC pathway. Female (●) or male (○)
C57BL/6 mice were surgically infected with 107 CFU UTI89. (A) IBCs present in bisected
bladders 6 or 24 hpi were stained with X-gal and enumerated. Data from two independent
experiments with 5 mice per group are shown; bars indicate geometric mean. Dotted line
represents the limit of detection. There were no statistically significant differences between
sexes at either time point. (B) The morphology of IBCs in female (left) and male (right)
C57BL/6 were observed 16 hpi with GFP-expressing UTI89 via confocal microscopy. In both
sexes, early IBCs appeared as small (20 µm diameter) collections of intracellular bacteria with
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bacillary morphology, while mature IBCs comprised coccoid UPEC in >100-µm masses
Representative images of early (top) and mature (bottom) IBCs are shown.
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Figure 4. UPEC more readily colonize the male C3H/HeN bladder. Female (●) or male (○)
C3H/HeN mice were surgically infected with 107 CFU of UTI89. (A) Bladders were
homogenized at the indicated time points, serially diluted, and CFU enumerated. Each point
represents one mouse; bars indicate geometric mean. Data comprise three independent
experiments with 5 mice per group. Dotted line represents the limit of detection. Mice were
classified as chronically infected if 2-wpi bladder titers were > 104 CFU/bladder. Statistically
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significant differences between males and females are indicated (*** P < 0.001). (B) Bacteria
present in the intracellular (gentamicin-protected; P=0.18) or extracellular (gentamicin-sensitive;
P=0.38) compartments of bladders from female (●) or male (○) C3H/HeN mice at 6 hpi were
enumerated. Aggregate data from three independent experiments with 5 mice per group are
shown. (C) IBCs present in bisected bladders 6 and 24 hpi in female (●) or male (○) C3H/HeN
mice were enumerated by microscopy following X-gal staining. Data from three independent
experiments with 5 mice per time point are shown.
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Figure 5. Male and female C3H/HeN hosts exhibit modest differences in bladder cytokine
expression during acute cystitis. Female (●) or male (○) C3H/HeN mice were surgically
infected with UTI89. Bladders were homogenized 6 or 24 hpi and centrifuged to remove cellular
debris before cytokine expression was measured. Bars represent the mean from 5 individual
mice per time point from two independent experiments.

Samples were assayed in duplicate.

Statistically significant differences between sexes are indicated (* P < 0.05; ** P < 0.01).
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Figure 6. Male C3H/HeN mice develop chronic cystitis. Female (●) and male (○) C3H/HeN
mice were surgically infected with 107 CFU of UTI89 and monitored for 4 wpi. (A and B)
Weekly urine bacterial titers and corresponding 4 wpi bladder titers were enumerated in female
(A) and male (B) mice following infection. Solid lines connect corresponding urine titer time
points and 4 wpi bladder titers (Bladder) from each individual mouse. Dashed horizontal lines
represent the cutoff for significant bacteriuria (104 CFU/ml). Dotted horizontal lines show the
limit of detection. Data were compiled from 2 independent experiments. (C and D) Paraffinembedded bladder sections 4 wpi from persistently bacteriuric female (C) and male (D)
C3H/HeN mice were examined by hematoxylin & eosin and light microscopy. Scale bars
approximate 50 µm.
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Figure 7. UPEC display similar bacterial morphology and luminal colonization in
chronically infected male and female C3H/HeN mice. Female (A) or male (B) C3H/HeN
mice were surgically infected with UTI89 and followed for 2 wpi. The bladders of mice that
displayed persistent bacteriuria were examined via immunofluorescence and confocal
microscopy; representative images are shown.
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Figure 8. Female and male mice with chronic cystitis display similar elevations in bladder
pro-inflammatory cytokines. Female (●) and male (○) C3H/HeN mice were surgically infected
with 107 CFU UTI89 and followed for 2 wpi. Bladders were homogenized and centrifuged to
remove cellular debris before cytokine expression was measured. Mice were grouped as
resolved or chronic, as outlined in Methods. Bars represent geometric means, with each point
indicating an individual mouse, assayed in duplicate. Data are shown from three independent
experiments. Statistically significant differences between chronic and resolved groups are
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indicated (* P < 0.05; ** P < 0.01; *** P < 0.001). No significant differences were observed
between sexes.
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Figure 9. Male C3H/HeN mice display acute inflammatory biomarkers predictive of
chronic outcome. Female (●) and male (○) C3H/HeN mice were surgically infected with 107
CFU of UTI89 and monitored for 2 wpi. Sera was collected 24 hpi and cytokine content
measured by multiplex bead array. Mice were grouped as resolved or chronic, as outlined in
Methods. Bars represent geometric means, with each point indicating an individual mouse,
assayed in duplicate. Aggregate data from three independent experiments are shown.
Statistically significant differences between chronic and resolved groups are indicated
(* P < 0.05). No significant differences were found between sexes. Statistical comparisons in
male serum IL-5, G-CSF, and KC were likely limited by the lack of n of resolved males.
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Figure 10. Male C3H/HeN mice develop severe pyelonephritis and 100% penetrant renal
abscess. Female (●) and male (○) C3H/HeN mice were surgically infected with 107 CFU
UTI89. (A) Kidney pairs were homogenized, serially diluted, and CFU enumerated at the
indicated time points. Each point represents one mouse; bars indicate geometric mean. The
dotted horizontal line represents the limit of detection. Data comprise three independent
experiments of 5 mice per group. Statistically significant differences between sexes are
indicated (*** P < 0.001). (B) Following autopsy, gross renal abscesses were observed in male,
but not female, C3H/HeN mice 2 wpi. A representative image of the stomach (St), spleen (Sp)
and abscessed left kidney (K) of a male C3H/HeN mouse 2 wpi is shown. (C and D) Paraffinembedded kidney sections 2 wpi from male C3H/HeN mice were examined by Gomori
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trichrome stain and light microscopy. Representative images illustrate (C) areas of necrotic
abscess and (D) diseased renal cortex; areas of collagen deposition appear blue (scale bars, 50
µm).
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Figure 11. Male C3H/HeN surgically infected with a urosepsis isolate, CFT073, develop
more severe chronic UTI. Female (●) or male (○) C3H/HeN mice were surgically infected
with 107 CFU of CFT073. Bladders (left) and kidneys (right) were homogenized 2 wpi, serially
diluted, and CFU enumerated. Eight of 9 males had visible renal abscess formation. Each point
represents one mouse; bars indicate geometric mean. Data comprise two independent
experiments with 4 or 5 mice per group. Dotted line represents the limit of detection.
Statistically significant differences between males and females are indicated (** P <0.01; *** P
< 0.001).
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Figure 12. Male C3H/HeN develop severe renal abscess and fibrosis. Male C3H/HeN mice
were surgically infected with 107 CFU UTI89. Paraffin-embedded kidney sections 2 wpi were
examined by Gomori trichrome stain and light microscopy. Representative image at low-power
magnification illustrates cortical and medullary abscesses. Areas of collagen deposition appear
blue. Scale bar, 200 µm.
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Figure 13. Testosterone enhances susceptibility to chronic UTI. (A) Sham-operated (●) and
ovariectomized (OVX; ▲) C3H/HeN female mice were surgically infected with 107 CFU of
UTI89 4 weeks post-operatively (at 9 weeks of age). Bladders (left) and kidney pairs (right)
were homogenized, serially diluted, and CFU enumerated 2 wpi. Each point represents one
mouse; bars indicate geometric mean. Data comprise three independent experiments of 5 mice
per group. (B) Sham-operated (○) and castrated (∆) C3H/HeN male mice were surgically
infected with 107 CFU of UTI89 four weeks post-operatively (9 weeks of age). Bladders (left)
and kidney pairs (right) were homogenized, serially diluted, and CFU enumerated 2 wpi. Each
point represents one mouse; bars indicate geometric mean. Data comprise three independent
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experiments of 5 mice per group. The dotted horizontal line shows the limit of detection. (C)
Sham-operated male C3H/HeN mice were subcutaneously implanted with slow-release placebo
pellets 5 days post-operatively, and castrated males were implanted with placebo or testosterone
pellets. Mice were surgically infected 4 weeks post-gonadectomy (at 9 weeks of age). Bladders
(left) and kidney pairs (right) were homogenized, serially diluted, and CFU enumerated 2 wpi.
Each point represents one mouse; bars indicate geometric mean. Data comprise three
independent experiments of 4-5 mice per group. The limit of detection is indicated with the
dotted horizontal line. Statistically significant differences between experimental groups are
indicated (** P < 0.01; *** P < 0.001).
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Abstract
Females across the lifespan and certain male populations are susceptible to urinary tract
infections (UTI). The influence of sex on UTI is incompletely understood, in part because
preclinical modeling has been performed almost exclusively in female mice. In recent studies
using a new mini-surgical bladder inoculation model, male C3H/HeN mice displayed enhanced
68

susceptibility to severe pyelonephritis; most males developed renal abscess, a complication rare
in female mice. Here, we reveal that within developing renal abscesses, uropathogenic
Escherichia coli (UPEC) formed dense intratubular, biofilm-like communities sheltered from
infiltrating leukocytes by a fibrotic tubular epithelium. Formation of intratubular communities
required type 1 pili, heretofore widely viewed as a virulence factor only in the bladder.
Administration of exogenous testosterone in C3H/HeN females also imparted susceptibility to
severe pyelonephritis and abscess formation. Susceptibility in both sexes was potentiated with
5α-dihydrotestosterone, and males with androgen receptor deficiency were protected from severe
pyelonephritis, demonstrating that specific activation of the androgen receptor augments UTI
severity in both sexes. Visualization of intratubular UPEC communities illuminates early renal
abscess pathogenesis and portends new studies of host-pathogen interactions in this niche. Our
data also suggest that androgen modulation may represent a novel therapeutic route to combat
recalcitrant or recurrent UTI.

Introduction
Bacterial infection of the urinary tract represents one of the most common human infectious
diseases and imposes a taxing burden on society; approximately 10 million primary care provider
visits annually are for uncomplicated lower urinary tract infection (UTI), incurring >$2 billion in
economic costs (1, 2). Ascension of uropathogens to the kidneys, resulting in pyelonephritis or
urosepsis, is associated with mortality and threatens lifelong morbidity, including renal scarring
and attendant risks of hypertension and chronic kidney disease, despite appropriate initial
antibiotic treatment (3, 4). These contemporary challenges to the human host manifest in an era
in which the primary causative agent of UTI, uropathogenic Escherichia coli (UPEC), displays
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unprecedented global prevalence and breadth of antimicrobial resistance (5). It is therefore
critical to understand bacterial and host mechanisms of disease in the kidney to illuminate novel
therapeutic routes to combat these serious infections and their sequelae.
Preclinical modeling of ascending pyelonephritis has been constrained by a lack of
susceptible female murine models and technical inability to access the male mouse bladder via
catheter (6, 7). To decipher sex differences in the disease, we recently developed a minimally
invasive surgical bladder inoculation model enabling direct comparison of male and female
hosts. After equal intravesical inoculation with UPEC, male mice of multiple genetic
backgrounds developed much more severe renal infection than females. While female mice
rarely form kidney abscess, we observed macroscopic, bilateral renal abscess and extremely high
kidney UPEC burdens in >90% of infected C3H/HeN males by 2 wk post infection (wpi) (7).
The C3H background is known to exhibit vesicoureteral reflux (VUR), a translationally relevant
feature because VUR is a major risk factor for upper-tract UTI, particularly in affected children
(8). Moreover, micro- and macroscopic abscess formation is a pathological feature of
pyelonephritis in humans (9), and the severity of inflammation correlates with subsequent renal
scarring in several models of renal injury (10, 11). The present model therefore enables the
discovery of niches and mechanisms exploited by UPEC for growth and persistence in the
kidney en route to formation of renal abscess in the setting of ascending pyelonephritis.
We previously reported that castration in male C3H/HeN mice prior to induction of UTI
mitigated the development of chronic cystitis, severe pyelonephritis, and renal abscess, while
ovariectomy had no effect on chronic outcome in females (7). Furthermore, exogenous
testosterone replacement in castrated male mice complemented the severe UTI phenotype,
implicating androgens in susceptibility to severe UTI (7). As these findings were developed in
70

male mice, it was unknown if androgen-driven UTI susceptibility extends to females, in whom
UTI is substantially more prevalent overall (1, 12, 13). Here, we interrogated the temporal
course of bacterial localization within developing renal abscesses and defined hormonal
signaling pathways that influence UTI susceptibility. UPEC formed dense, biofilm-like
communities filling renal tubules at the center of developing abscesses, and were sheltered from
surrounding inflammatory cells through fibrosis associated with tubular epithelia. These
intratubular communities and associated severe pyelonephritis were induced in female mice by
elevating androgen levels, phenocopying the course observed in male C3H/HeN mice. Further,
pharmacological and genetic manipulation demonstrated that specific activation of the androgen
receptor promotes development of severe pyelonephritis in both female and male hosts.

Results
Ascending renal abscesses emerge in male C3H/HeN mice in a narrow temporal window.
As traditional preclinical modeling of UTI is limited to female mice, and females of most
laboratory strains are highly resistant to pyelonephritis and renal abscess formation (6, 7, 14, 15),
there is a significant gap in our understanding of the pathogenesis and development of ascending
renal abscesses. However, by 2 wpi, over 90% of C3H/HeN males undergoing mini-surgical
bladder inoculation develop gross bilateral renal abscess (7). This model can thus be used to
interrogate the anatomic and temporal details of abscess onset in the kidney following
intravesical inoculation of UPEC. We previously showed that surgically infected male
C3H/HeN mice develop higher bladder and kidney UPEC burdens than females 24 hours post
infection (hpi), but do not yet display renal abscesses at this interval (7). Here, we surgically
infected male C3H/HeN mice with the cystitis-derived UPEC isolate UTI89 and monitored
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abscess progression over time. Histological examination of kidneys 3 days post infection (dpi)
from mice exhibiting urine and bladder bacterial titers >104 CFU (predictive of the development
of pyelonephritis (7)) demonstrated no evidence of abscess and only scant neutrophilic
inflammation near the renal pelvis, with no apparent inflammation or tissue damage in the renal
cortex or medulla (Figure 1A and Figure 2). Visualized bacteria were limited to the renal pelvis
and calyces (Figure 1B, black arrowhead), and immunofluorescence microscopy identified no
UPEC outside the renal pelvis (data not shown).
By 5 dpi, a small proportion of infected mice (4 of 15, 27%) exhibited grossly evident
abscess at necropsy. Immunofluorescence microscopy at this time point revealed small
intraluminal collections of bacillary UPEC, distributed from the collecting system (Figure 1C,
white arrowheads) to the proximal tubule (Figure 1D, white arrowhead and Figure 3). The
tubules housing many of these UPEC communities reflected cellular injury and were surrounded
by small numbers of infiltrating interstitial neutrophils, though inflammation was not evident
within the tubular lumina (Figure 1E-G). Nine of 10 (90%) infected males developed gross
renal abscess by 6 dpi (Figure 1H), equivalent to the frequency observed at 2 wpi (7). Thus,
ascending renal abscesses in this model develop precipitously between 5 and 6 dpi, signifying
rapid UPEC colonization of the renal parenchyma in this time window.

UPEC assemble an intratubular biofilm-like nidus within ascending renal abscesses.
The microscopic organization of UPEC during renal abscess formation has not been
elucidated. Complete sectioning and microscopic examination of kidneys from infected male
C3H/HeN mice displaying persistent bacteriuria 2 wpi revealed populations of bacteria in the
centers of dense neutrophilic lesions (Figure 4A). Abscesses appeared predominantly at the
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corticomedullary junction, with the PMN lesions surrounded by a rim of necrotic material
(Figure 4A). UPEC were located entirely within the intratubular space, forming biofilm-like
communities and adopting a tightly packed coccoid morphology by 2 wpi (Figure 4B, C) in
contrast to their loosely associated and bacillary morphology 5 dpi (Figure 1G). Staining with
anti-E. coli antibodies confirmed that UPEC comprised the entirety of this intratubular nidus at
the center of renal abscesses (Figure 4C) and were rarely identified outside of the tubular lumen.
Frequently, we observed multiple, discrete intratubular bacterial collections in close proximity
within the same neutrophilic lesion (Figure 4D), suggesting that UPEC colonized some length of
interconnected nephrons. Viewed at low power, kidney segments involved with inflammation
distinctly followed a wedge-shaped pattern, while other areas of kidney were spared (Figure
4E). In conjunction with findings at earlier time points (Figure 1), these data suggest that
ascending UPEC gain access to and colonize an isolated papillary collecting duct pyramid and
(subsequently) multiple associated nephrons via robust intraluminal replication to nucleate
abscess formation within a given segment of the kidney.
Abscesses rarely develop in female C3H/HeN mice (6, 7, 16), but we did identify an abscess
with identical bacterial intratubular community morphology in one female mouse (out of >30
examined 2 wpi; Figure 5). Thus, bacterial organization within renal abscesses was preserved
between sexes, but male sex conferred a dramatically increased risk for this upper-tract
complication following UPEC inoculation of the bladder.

Tubular fibrosis separates intratubular UPEC communities from recruited phagocytes.
By 2 wpi, recruited neutrophils filled the renal interstitium surrounding UPEC-colonized
tubules (Figure 4). Nearby tubules were largely destroyed or replaced by leukocytic infiltrates
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or demonstrated other histologic signs of injury (e.g., thyroidization and atrophy), while tubules
harboring bacterial communities retained their structure (Figure 4B, D). Gomori trichrome
staining indicated that infected tubules were fibrotic and encapsulated the UPEC abscess
communities (Figure 6A, arrowheads). Most of these colonized tubules displayed no PMNs
within the tubular lumen or bacterial mass (Figure 4 and 6A); when intratubular phagocytes
were occasionally identified, they were associated with a breach in the fibrotic epithelial capsule
(Figure 6B, C). Thus, we posit that UPEC infection provokes fibrosis of the tubular epithelium,
in turn protecting the bacterial nidus from phagocytic attack.
Notably, UTI89-infected male C3H/HeN mice did not succumb to their severe infection,
surviving for at least 30 wpi despite persistence of high renal bacterial burdens and abscesses,
and maintaining sterile blood and spleen cultures (data not shown). Thus, while male kidney
infection with UTI89 in this model is not self-limiting, it also does not result in lethal sepsis. It
has been previously reported that mice with functional deficiency of Toll-like receptor 4 (TLR4),
which exhibit a markedly delayed neutrophil response to UTI, do not develop renal abscesses
even following direct renal injection of UPEC (6, 17, 18). We tested how TLR4 deficiency
would impact ascending renal infection by surgically infecting male and female mice of the
C3H/HeJ strain, insensitive to lipopolysaccharide owing to a TLR4 mutation. At 3 dpi, infected
male C3H/HeJ mice displayed significantly higher renal (P=0.0010) and bladder (P=0.0010)
bacterial burdens compared to female C3H/HeJ mice (Figure 6D) and did not exhibit visible
renal abscess. Infected males succumbed to infection between 3 and 7 dpi, while most females
survived through the period of observation (2 wpi) (P=0.0274; Figure 6E). Of note, the timing
of demise in infected male C3H/HeJ mice coincided with the window of abscess development
we observed in C3H/HeN mice (see Figure 1). No infected C3H/HeJ males displayed gross
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renal abscess at post-death necropsy or (in the minority that survived) at 2 wpi, despite all having
kidney bacterial burdens >107 CFU. Thus, TLR4-mediated signaling, expression, or activation
are not responsible for sex differences in UTI; more importantly, abscess formation in the TLR4competent host protects from lethal systemic infection. Collectively, these data support a model
in which innate cellular responses and tubular fibrosis enable the host to contain infection and
prevent systemic dissemination; however, this strategy also generates a sheltered intratubular
niche for UPEC following their ascension from the bladder.

Type 1 pili are required for renal abscess formation.
Arriving in the female bladder, UPEC exploit mannose moieties decorating the luminal
epithelial surface as the receptor for their major virulence determinant, the adhesive type 1 pilus;
absence of type 1 pili or the tip adhesin FimH abolishes bacterial attachment and abrogates
cystitis (19, 20). However, a role for type 1 pili in pyelonephritis has not been extensively
explored. We used our surgical bladder inoculation model to investigate if type 1 pili were
required for formation of intratubular UPEC communities within the kidney. Male C3H/HeN
mice surgically inoculated with UTI89ΔfimH resolved infection by 2 wpi, with markedly lower
bladder and kidney bacterial loads (many sterile) in UTI89ΔfimH-infected mice (P<0.0001 vs.
WT UTI89; Figure 7A). While all males infected with WT UTI89 developed gross renal
abscess, we observed no abscess development in the kidneys of UTI89ΔfimH-infected mice
(P<0.0001 by Fisher exact test). These marked differences in infection outcome were evident
despite similar numbers of UTI89 and UTI89ΔfimH reaching the male kidneys by 1 h after
bladder inoculation (P=0.975; Figure 8), demonstrating that type 1 pili are required for
colonization of the kidney and formation of intratubular communities in this model.
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Immunofluorescence microscopy confirmed that type 1 pili are expressed by UPEC within
intratubular abscess communities 2 wpi (Figure 7B).

Androgen exposure aggravates UTI severity in female C3H/HeN mice.
As detailed above, castrated C3H/HeN males (like C3H/HeN females) rarely developed renal
abscess, but susceptibility to severe UTI was restored by testosterone complementation (7).
However, it was unclear if elevated testosterone levels in females could likewise amplify UTI
severity and enhance abscess development. To address this question, we implanted slow-release
testosterone or placebo pellets in female C3H/HeN mice 4 wk prior to induction of UTI. As
expected, testosterone pellet implantation significantly increased serum testosterone compared to
placebo-treated females, in fact mirroring serum testosterone levels seen in WT males of similar
age (21, 22) (Figure 9A). Treatment of females with exogenous testosterone induced severe
UTI 2 wpi (Figure 9B); significantly higher bladder (P=0.0102) and kidney (P=0.002) bacterial
burdens were present in testosterone-treated females compared to placebo-treated controls.
Consistent with prior results, a minority (36%) of placebo-treated females developed chronic
cystitis, compared to 64% of androgenized females. More strikingly, androgen treatment led to
development of gross abscess in at least one kidney in 64% of females, compared to 0 of 14
placebo controls (P=0.0006). Abscesses in androgenized females appeared grossly and
microscopically identical to those found in C3H/HeN males (7), recapitulating the time course
and appearance of intratubular UPEC communities. Of note, while our surgical inoculation
model does induce acute and chronic prostatitis with UTI89 in C3H/HeN males ((7) and Figure
10), the prostate does not contribute anatomically or otherwise to androgen-induced severe UTI
(as testosterone-treated females, of course, lack prostates). In total, these data illustrate that
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elevated circulating testosterone predisposes to severe UTI and renal abscess formation
independent of biological sex.

Androgen receptor activation drives UTI severity.
We next aimed to identify the signaling pathway(s) by which testosterone acts to induce
severe UTI. It is plausible that testosterone supplementation would perturb levels of other
hormones in the hypothalamic-pituitary-gonadal (HPG) axis via its negative feedback on
gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating
hormone (FSH). In this scenario, increased GnRH, LH, and/or FSH could be protective in
castrated males, while decreased secretion of these hormones in androgenized hosts could
promote UTI susceptibility. Refuting this possibility, we previously found that while
orchiectomy in males dramatically attenuated UTI, ovariectomy in females (which would
activate the HPG axis similarly to castration in males (23)) had no influence on UTI outcome (7).
This finding in conjunction with our ability to induce severe UTI in females via androgen
treatment (Figure 9B) eliminates alteration in GnRH, LH, or FSH levels as a cause of increased
UTI severity in androgenized hosts.
There are two primary routes by which testosterone could drive regulatory changes which
lead to enhanced UTI. In one pathway, testosterone could undergo peripheral aromatization by
aromatase, yielding estradiol which would then activate the estrogen receptor. To specify if this
was the case, we tested whether an aromatase-resistant and more potent androgen receptor (AR)
agonist, 5α-dihydrotestosterone (DHT), could complement UTI severity in castrated males. We
implanted slow-release DHT or placebo pellets 1 day after castration or sham operation in
C3H/HeN males, then induced UTI 4 wk later. Consistent with our previous results, castration
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attenuated bladder (P=0.041) and kidney (P=0.0063) bacterial burdens 2 wpi in placebo-treated
males (Figure 11A). Treatment of castrated males with exogenous DHT reversed the effects of
castration (Figure 11A), mirroring the complementation seen with testosterone (7). Organ
bacterial burdens in castrated, DHT-treated males were similar to those in sham-operated,
placebo-treated males, with both groups developing bilateral gross renal abscess in the majority
of animals. Likewise, treatment of female C3H/HeN mice with DHT led to significantly higher
bladder bacterial burdens 2 wpi (P<0.0001) and a higher frequency of chronic cystitis (P=0.0025
by Fisher exact test) in comparison to placebo-treated females (Figure 11B). DHT treatment
also induced dramatically increased kidney titers (Figure 11B, P<0.0001), and abscesses formed
in 73% of these females (P<0.0001 vs placebo). Thus, peripheral aromatization of testosterone
does not mediate susceptibility to severe UTI. Of additional note, mice in these female-only
experiments were infected via the traditional catheter route, demonstrating that the observed
severe UTI phenotypes and their androgen dependence are not attributable to any aspect of the
surgical infection methodology.
While classical AR activation is the most robust mechanism of androgenic signaling, new
alternative signaling pathways that alter transcription independent of the androgen receptor have
recently emerged (24, 25). To test classical AR involvement, we first undertook treatment with
flutamide, an imperfect AR antagonist (26, 27). Flutamide administration over 4 wk prior to
infection offered modest protection to C3H/HeN males 2 wpi compared to placebo-treated males
in the bladder (P=0.0027) and kidney (P=0.0047) (Figure 12A), but did not attenuate disease to
the degree seen following castration (7). We next adopted a genetic approach, using testicular
feminization (Tfm) mice, which encode a frameshift mutation disrupting the steroid-binding
domain of the AR, rendering these mice insensitive to classical AR signaling (28, 29). These
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mice are maintained in a C57BL/6 Aw-j (agouti) background with the ARTfm allele in repulsion to
an Eda mutation (tabby) on the wild-type X chromosome, a scheme originally engineered to help
distinguish offspring genotype by coat color (28). However, a fitness defect arising from the
Eda mutation in Eda-/- AR+/+ females or Eda-/Y AR+/Y males limited the number of such ARwild-type littermates we could generate. Because of this, and to exclude any effect of the Eda
mutation on UTI phenotypes, we also analyzed WT C57BL/6 Aw-j males (AR+/Y Eda+/Y) and
females (AR+/+ Eda+/+).
We compared renal colonization 24 hpi following surgical induction of UTI in the 5
genotypes. As expected, AR+/Y Eda-/Y (tabby males) and AR+/Y Eda+/Y (WT males)
demonstrated high and statistically equivalent kidney titers 24 hpi, as we had previously
observed in WT C57BL/6J males (7). In contrast, females with wild-type AR expression, AR+/+
Eda-/- (tabby females) and AR+/+ Eda+/+ (WT females), each displayed low renal bacterial
burdens, with most females resolving infection (Figure 12B). Both AR+/Y Eda+/Y WT males
and AR+/Y Eda-/Y tabby males demonstrated significantly higher kidney titers than AR+/+ Eda+/+
WT females (P=0.0159 and P=0.0238, respectively).

Importantly, the majority of ARTfm/Y

Eda+/Y mice (TFM males) resolved renal infection by 24 hpi, with kidney bacterial burdens
significantly lower than AR+/Y Eda+/Y WT males (P=0.0043) and AR+/Y Eda-/Y tabby males
(P=0.0208) but indistinguishable from AR+/+ Eda+/+ WT females (P=0.4974). These data specify
that androgen receptor activation induces susceptibility to severe upper-tract UTI in both sexes.

Discussion
In this study, we demonstrate that UPEC establishes intraluminal communities within kidney
tubules, arising precipitously in androgenized hosts within a narrow temporal window to
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nucleate nascent renal abscesses. These intratubular UPEC communities were apparently
protected from phagocytosis, as histology reflected an inability of infiltrating inflammatory cells
to cross the fibrotic tubular epithelium surrounding these communities. Finally, we show that
androgen receptor activation in either host sex underlies increased susceptibility to
pyelonephritis and renal abscess formation, a paradigm with significant potential for translational
impact.
Abscesses were focal or multifocal, located adjacent to other, uninvolved segments of renal
parenchyma and adopting the pattern of a collecting duct unit. This observation suggests that
among UPEC that reach the renal pelvis, only a fraction are ultimately successful in accessing
and persisting within selected nephrons. While we often contemplate the process of uropathogen
ascension up the urethra or from the ureterovesical junction to the kidney (not specifically tested
in C3H mice, given their vesicoureteral reflux), it is equally important to consider the “third
ascension” from the renal pelvis and calyces to more proximal areas of the nephron. The
virulence mechanisms or host factors which enable this tubular ascension are largely unknown,
although some studies have implicated immunologic factors influencing ascension and
persistence in the collecting duct (30-32).
Once gaining a foothold, UPEC replicate in the intraluminal space, ultimately infecting an
entire collecting duct unit. While infiltrating neutrophils may destroy some infected tubules,
successful bacterial colonies are separated from surrounding phagocytes by tubular epithelial
fibrosis, with inflammatory cells only being visualized when breaches in the epithelium are
evident (Figure 6). In other disease models, including ischemic kidney injury, transmigration of
neutrophils across the tubule epithelium appears to be unimpaired (33-35). Fruitful future
investigations in the present model will illuminate pathogen strategies or host factors (anatomic
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features such as the basement membrane (36), or cellular programs leading to fibrosis) that
impede neutrophil migration into the abscess community. Importantly, while male C3H/HeN
mice are unable to resolve renal infection, their survival indicates that abscess formation
successfully restricts the spread of infection, either to nearby unaffected renal parenchyma or
systemically into the blood. In contrast, congenic males with diminished innate responses fail to
form abscesses and succumb to infection (Figure 6). We therefore propose a model whereby
ascending abscess development is a double-edged sword: bacteria are contained within the
tubule via fibrosis, preventing overwhelming systemic disease, but this process creates a
privileged site for bacterial replication where surrounding inflammatory cells within the abscess
lesion are unable to access the expanding UPEC community.
The UPEC intratubular communities observed within the kidney display remarkable parallels
to earlier descriptions of intracellular bacterial communities within bladder epithelium (37-40).
Though the microenvironment is presumably quite different in these two niches, UPEC in both
these colony types evolves morphologically from a bacillary morphology (Figure 1) to dense
biofilm collections of coccoid bacteria (Figure 4). While the importance of type 1 pili has been
detailed extensively during cystitis and for intracellular bladder invasion and replication is (19,
20, 41), relatively few studies have interrogated its role in pyelonephritis. One study
demonstrated a role for type 1 pilus-mediated interbacterial binding within the tubule following
microinjection of UPEC into the nephron (42). Here we found that type 1 pili were required for
ascending intratubular community development, with expression throughout the abscess
community (Figure 7). This finding suggests that anti-virulence strategies directed at type 1 pili
assembly (pilicides (43)) or interbacterial binding (mannosides (44, 45)) may interrupt the
development of renal abscesses. Overall, the thematic similarity of UPEC morphology in
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bladder and kidney hints that UPEC uses conserved programming to proliferate and to ultimately
subvert the innate cellular response through biofilm formation within these niches (46). Such
community formation also likely impairs antibiotic action, correlating with a clinical need for
prolonged antibiotic therapy in severe pyelonephritis and renal abscess. Even before
development of frank abscess (which clinically often requires percutaneous or surgical drainage
to accomplish resolution), the fibrotic barrier may limit antibiotic diffusion to the bacterial nidus.
Further, occlusion of renal tubules by UPEC would preclude local transit of antibiotics in the
urinary space as well as inhibit antibiotic action and penetration into the biofilm community.
Androgen receptor activation clearly induced susceptibility to severe pyelonephritis and
abscess development; genetic inhibition of AR signaling attenuated severe UTI. The effect of
AR activation with DHT was consistent across both sexes, demonstrating that organizational
anatomic differences (including the prostate) do not contribute to this phenotype. Further
investigation is required to specify the AR-regulated gene networks that mediate UTI
susceptibility in androgenized hosts. The observation of severe UTI in androgenized females
offers an alternative, non-surgical approach to bladder inoculation (as female mice can be
routinely catheterized) in future studies of severe pyelonephritis and renal abscess formation.
We previously saw no appreciable phenotype following estrogen depletion (7), and have ruled
out a contribution from peripheral aromatization (Figure 11). This is in contrast to a current
paradigm, supported by some studies, in which estrogen levels are believed to influence UTI
pathogenesis (47-51). Instead, we argue that even modest elevations in circulating testosterone
(which often parallel increases in estradiol (52-54)) in male and female patients may have a
greater effect on both bladder and kidney susceptibility to infection. We present proof of
concept that the course of severe UTI can be altered by AR antagonism, suggesting that
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antiandrogen therapy may represent an avenue for adjunctive therapy in treatment-refractory
cases of complicated UTI. Flutamide is rarely used in fully androgenized patients because of its
relatively low AR affinity, inability to block AR translocation to the nucleus, and elicitation of
increased androgen secretion in males (26, 27, 55-57). The efficacy of newer-generation nonsteroidal antiandrogens (bicalutamide, enzalutamide, etc.) in mitigating UTI severity remains to
be explored in preclinical models.
Our findings carry notable relevance to certain human patient populations, suggesting that
individuals with elevated androgen levels carry an increased risk of UTI. Certainly, the human
population with the highest circulating testosterone, adolescent males (58), have the lowest rates
of UTI (12), as differences in urogenital anatomy (compared with women) comprise the key
defense against UTI in otherwise healthy men (7). In fact, when these anatomic barriers are
compromised or bypassed, epidemiologic data reflect increased morbidity and mortality in men
who do develop pyelonephritis and complicated UTI, as compared with women (59-62). The
present finding that androgen-mediated UTI receptivity likewise affects females greatly extends
the translational implications of our work. Most clinical studies of polycystic ovary syndrome
(PCOS), a common hyperandrogenic state in young women, have not specifically ascertained
UTI incidence in this population. However, in the few studies in which such data were collected,
women with PCOS exhibited increased rates of UTI compared to healthy females (63-65), and
UTI incidence decreased in affected women following androgen deprivation therapy (63). In
murine models of PCOS, mice overexpressing LH (and consequently testosterone) develop
spontaneous pyelonephritis and associated renal damage (66-69). Additionally, an untold
number of women without overt hyperandrogenism might be at higher risk for developing UTI
because of circulating testosterone levels near the upper limits of the “normal” range, a potential
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causative relationship that mandates further study. In a related vein, male infants (e.g., those
under 6 months of age) presenting with UTI outnumber their female counterparts, with male UTI
rates falling steadily from the neonatal period to late infancy (70-78). This epidemiologic
phenomenon closely parallels the postnatal surge in testosterone in male infants that reaches
pubertal levels shortly after birth, then steadily wanes to a prepubertal baseline by 6-9 months of
age (79-82). We speculate that elevated testosterone levels in male infants are an
underappreciated contributor to increased UTI rates in male infants less than 9 months of age.
While some male infant UTI has been commonly ascribed to indistinct “urodynamic
immaturity,” testosterone activity may actually underlie UTI risk, especially in the two-thirds of
such infants (after first febrile UTI) who lack demonstrable vesicoureteral reflux or obstruction
(83).
In summary, we present detailed snapshots of the development of ascending UPEC renal
abscess, in an emerging model applicable to both host sexes. We further demonstrate that
activation of the androgen receptor potentiates severe UTI in male and female hosts. Ongoing
work will specify the mechanisms by which AR agonism influences host-pathogen interaction
and immune control of UPEC infection in the kidney, illuminating potential avenues to
translational intervention in patients with recurrent or severe UTI.

Materials and methods
Bacteria
Uropathogenic E. coli strain UTI89 was isolated from the urine of a patient with cystitis (84).
The ΔfimH deletion strain was generated using a Lambda red recombinase scheme (85) and
confirmed by direct sequencing. For infections, bacteria were grown in static Luria-Bertani (LB)
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broth for 16 h at 37°C. Cultures were centrifuged for 10 min at 7,500 × g at 4°C before
resuspension in sterile phosphate-buffered saline (PBS) to a final density of 4 × 108 CFU/mL.

Surgical and catheterization murine models of UTI
All animal care and use protocols received prior approval from the Washington University
Animal Studies Committee. Experiments were conducted in C3H/HeN (Envigo, Indianapolis,
IN), C3H/HeJ (Jackson Laboratories, Bar Harbor, ME), or C57BL/6 Aw-J/Aw-J (Jackson
Laboratories) strains. Mice were housed under constant temperature and humidity, with a 12 h
light/dark cycle. Surgical infection of male or female mice was carried out as described
previously (7). Mice aged 8-9 wk were anesthetized with inhaled 3% isoflurane, and the
abdomen was shaved and sterilized with 2% chlorhexidine solution. A 3-mm vertical, midline
incision was made over the bladder through the skin and peritoneum. The bladder was
aseptically emptied before injection of 50 µL containing 1-2 × 107 CFU into the bladder lumen
over 10 s. The bladder was allowed to expand for an additional 10 s before the needle was
removed, and the peritoneum and skin were closed with sutures. UTI was allowed to proceed
from 1 h to 4 wk. For certain female-only experiments as indicated, UTI was initiated by
catheter in mice aged 8-9 wk via instillation of 50 µL containing 1-2 x 107 CFU into the bladder
by transurethral catheterization (86-88).

Determination of urine and tissue bacterial loads
Where indicated, we obtained post-infection, clean-catch urine samples using gentle
suprapubic pressure for serial dilution and plating to enumerate CFU/mL urine. At the indicated
time points, mice were euthanized via CO2 asphyxiation, and bladders and kidney pairs were
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aseptically removed and homogenized in 1 ml or 0.800 ml sterile PBS, respectively. To
ascertain prostate bacterial loads, the male urogenital system was removed en bloc and the
prostate was micro-dissected under a light dissecting microscope as previously described (89).
Briefly, the vas deferens, seminal vesicles, bladder, ureters, prostatic urethra, and adipose tissue
were removed from the prostatic tissue before homogenization in 1 ml sterile PBS. We plated
serial dilutions of tissue homogenates on LB agar to enumerate bacterial loads. Where indicated,
infection in C3H/HeN mice was classified as “chronic” if all urine and endpoint bladder titers
contained >104 CFU/ml. “Resolved” mice demonstrated endpoint bladder burdens and at least
one urine time point <104 CFU/ml. Organ homogenates to be used for soluble cytokine analysis
were centrifuged at 15,000 × g for 5 min, and supernatants were stored at -80°C.

Tissue histopathology and immunofluorescence
Infected bladders and kidneys were bisected and fixed in 10% neutral buffered formalin for
24 h. Fixed tissues were embedded in paraffin, sectioned, and stained with H&E or with Gomori
trichrome stain. For immunostaining, unstained slides were deparaffinized, washed in PBS,
antigen retrieved by boiling in sodium citrate, blocked in 1% BSA, 0.3% Triton-X 100 in PBS
for 30 min at room temperature, and incubated with rabbit anti-E. coli (E3500-06C, US
Biological, Salem, MA) or rabbit anti-gel-purified type 1 pili (90) primary antibodies overnight
at 4°C. After washing in PBS, sections were stained with AlexaFluor 488-conjugated goat antirabbit IgG (Life Technologies, Grand Island, NY) secondary antibody and SYTO 61 red
fluorescent nucleic acid stain (Molecular Probes, Eugene, OR). Images were acquired on a Zeiss
Axio Imager M2 fluorescence microscope.
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Castration and androgen treatment
Male mice aged 4 wk were prepared for surgical castration with preoperative subcutaneous
injection of buprenorphine (0.05 mg/kg). Males were maintained under inhalation anesthesia
with 3% isoflurane via vaporizer and nose cone. Anesthetized mice were positioned supine, and
the scrotum was shaved and depilated with Nair (Church & Dwight Co., Ewing, NJ). The
operative field was rinsed with sterile water and disinfected with 2% chlorhexidine solution. A
1-cm ventral, midline incision was made in the scrotum, and the skin was retracted to expose the
tunica. The tunica was pierced, and the testis and vas deferens were mobilized from the incision.
The spermatic cord was clamped and ligated with 4-0 Vicryl above the epididymis, and the testis
and vas deferens were removed just below the ligature. The differential vessels and ducts were
replaced back into the tunica. This procedure was repeated on the contralateral side. The skin
incision was closed with Vetbond (3M Animal Care Products, St. Paul, MN). Where indicated,
60-day continuous release pellets containing 25 mg testosterone, 25 mg DHT, 75 mg flutamide,
or placebo (Innovative Research of America, Sarasota, FL) were implanted subcutaneously in
sterile fashion at the nape of the neck. DHT pellets were implanted 4 days following castration
or sham operation. In females or flutamide-treated males, testosterone, DHT, flutamide, or
placebo pellets were implanted at 4 wk of age. All mice were infected at 8-9 wk of age.

Serum testosterone analysis
Venous blood was collected by submandibular puncture using 5-mm steel lancets
(MediPoint, Mineola, NY) into Microtainer serum separation tubes (Becton Dickinson, Franklin
Lakes, NJ). Samples were allowed to clot for 90 min at room temperature before centrifugation
at 10,000 × g. Serum testosterone was measured by enzyme immunoassay (Immuno-Biological
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Laboratories, Minneapolis, MN) at the Ligand Assay and Analysis Core, University of Virginia
Center for Research in Reproduction (Charlottesville, VA). Each sample was measured in
duplicate and recorded as the mean.

Statistics
Organ bacterial loads and other numerical data were compared by the nonparametric MannWhitney U test. Survival analysis was performed with the Mantel-Cox log-rank test. 2x2
comparisons were performed using the Fisher exact test. P values <0.05 were considered
significant.
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Figures
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Figure 1. Timeline of renal abscess formation in C3H/HeN mice. Pie charts reflect the
proportion of male C3H/HeN mice exhibiting gross abscess formation at necropsy at the
indicated time points. At 3 dpi, histology demonstrates normal architecture (A) and bacteria
within the renal pelvis (B, black arrowhead). At 5 dpi, immunofluorescence identifies small
collections of UPEC (green; white arrowheads) in collecting ducts (C) and proximal tubules (D
and E are from adjacent sections); SYTO 61 stains nuclei red. Small numbers of neutrophils
surround infected tubules (E, F), and tubules bear modest collections of bacillary UPEC (inset
from F, shown in G). By 6 dpi, histologic evidence of abscess is fully established, with necrotic
lesions, loss of tubular architecture and replacement by neutrophilic infiltrate (H, black
arrowheads). Scale bars: A, 100 µm; B, 50 µm; C, 100 µm; D, 100 µm; E, 100 µm; F, 50 µm;
G, 20 µm; H, 200 µm.
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Figure 2. Male C3H/HeN do not have renal parenchymal involvement 3 dpi. At 3 dpi in
C3H/HeN males, there was no evident inflammation or damage in the renal cortex or medulla.
Scale bar, 200 µm.
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Figure 3. Male C3H/HeN develop microabscess 5 dpi. Low-power view (H&E) of infected
male C3H/HeN mouse kidney 5 dpi, showing largely preserved tubular architecture and
intraluminal bacterial collections. Scale bar, 200 µm.
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Figure 4. UPEC establish biofilm-like communities in a protected intraluminal niche.
Neutrophilic abscesses were seen throughout the renal parenchyma 2 wpi (A). Infected tubules
at this time point were filled with coccoid UPEC, as seen by H&E staining (B) or
immunofluorescence with anti-E. coli antibodies (green in C, inset shows magnified view; red
staining of host nuclei as well as green autofluorescence of tubular epithelium, best seen in upper
right, are also shown). In many infected kidneys, multiple infected tubules were identified within
a single large abscess lesion (D). Overall, the pattern of inflammation followed that of a wedge
of nephrons associated with an infected papillary collecting duct (duct of Bellini), generally
outlined by the gray dashed lines in (E). Scale bars: A, 200 µm; B, 50 µm; C, 20 µm; D, 50
µm; E, 200 µm.
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Figure 5. Female C3H/HeN are susceptible to UPEC intratubular abscess community
formation. Abscess identified 2 wpi in a single female C3H/HeN mouse, demonstrating an
H&E appearance identical to abscesses seen in a majority of male C3H/HeN mice. Features
include intratubular UPEC communities separated by tubular epithelia from intense neutrophilic
infiltrate, which has replaced much of the nearby tubular architecture.
Scale bar, 100 µm.
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Figure 6. Fibrotic tubular epithelium restricts infection but protects UPEC from
infiltrating phagocytes. Gomori trichrome staining of kidneys 2 wpi reveals that infected
tubules are fibrotic (A, yellow arrowheads). UPEC were undisturbed within infected tubules,
except when breaches allowed influx of neutrophils (B, C, H&E). Neutrophil influx was
necessary for containment of infection; when the TLR4-deficient C3H/HeJ strain was used, male
mice maintained significantly higher bladder and kidney titers than females 2 wpi (D,
***P=0.0010; dotted line indicates limit of detection) and were much more likely to succumb to
infection (E; n=10 per group, *P<0.0274), an outcome not observed in immunocompetent
C3H/HeN males. Scale bars, 50 µm.
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Figure 7. Type 1 pili are necessary for intratubular community formation. In C3H/HeN
males 2 wpi (A), bladder and kidney bacterial loads were significantly lower (with many organs
sterile) after infection with UTI89ΔfimH (filled diamonds) when compared with WT UTI89
(open circles; ***P<0.0001). Dotted line indicates limit of detection. Immunofluorescence with
anti-type 1 pilus antibody demonstrated expression of type 1 pili by coccoid UPEC within the
community (B and inset; scale bar, 20 µm). As in Figure 2, host nuclei are stained red with
SYTO 61, and green autofluorescence of tubular epithelium is present.
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Figure 8. UTI89ΔfimH ascend to the kidneys in numbers equivalent to wild-type 1 hpi.
Wild-type UTI89 and the fimH mutant are recovered at equal numbers from bladder and kidneys
1 h following mini-surgical bladder inoculation of C3H/HeN males. Dotted line indicates limit
of detection.
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Figure 9. Androgen exposure aggravates UTI severity in females. Female C3H/HeN mice
were subcutaneously implanted with placebo (filled circles) or long-release testosterone pellets
(filled triangles) 4 wk prior to induction of UTI. As anticipated, testosterone pellets increased
the serum testosterone to levels physiologically relevant to normal males (A, ***P<0.0001 vs
placebo). Organ harvest 2 wpi (B) revealed higher bacterial loads in females treated with
testosterone, in both the bladders (*P=0.0102) and kidneys (**P=0.002). Dotted line indicates
limit of detection.
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Figure 10. Surgical induction of cystitis in male C3H/HeN also induces prostatitis. Minisurgical inoculation of the bladder in C3H/HeN males results in durable prostate infection with
UPEC. Shown are prostate bacterial loads at the indicated time points. Dotted line indicates
limit of detection.
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Figure 11. Testosterone influence on UTI severity is not mediated via aromatization.
Bladder and kidney bacterial burdens were measured 2 wpi (A) in sham-operated C3H/HeN
males treated with placebo pellets (open circles), castrated males treated with placebo pellets
(open triangles), and castrated males receiving pellets of 5α-dihydrotestosterone (DHT), a potent
androgen not susceptible to conversion to estrogen via the action of aromatase (inverted
triangles). As seen previously, castration was protective against severe UTI (*P<0.041 in
bladder, **P<0.0063 in kidney vs sham-operated). Treatment of castrated males with exogenous
DHT reversed this effect (***P<0.0001 in both organs vs castrated males receiving placebo);
DHT-complemented males exhibited organ bacterial burdens equivalent to sham-operated,
placebo-treated males (A) and similarly developed gross renal abscess. (B) In an analogous way,
treatment of C3H/HeN females with DHT was associated with significantly higher bladder and
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kidney bacterial burdens 2 wpi (***P<0.0001 vs placebo). Dotted lines indicate limit of
detection.
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Figure 12. Androgen receptor activation enhances severity of UTI. (A) Male C3H/HeN
mice were implanted 4 wk prior to infection with a long-release subcutaneous pellet of flutamide
(a clinically well-established but imperfect AR antagonist; open triangles) or placebo (open
circles). Compared with mice receiving placebo, bladder and kidneys of flutamide-treated mice
harbored significantly lower bacterial loads 2 wpi (**P<0.01). (B) Renal bacterial loads 2 wpi
in five Eda and AR genotypes comprising phenotypic males (open circles) or females (filled
circles). Included strains are tabby males (AR+/Y Eda-/Y), WT agouti males (AR+/Y Eda+/Y),
androgen receptor-deficient (TFM) males (ARTfm/Y Eda+/Y), tabby females (AR+/+ Eda-/-), and
WT agouti females (AR+/+ Eda+/+). The renal bacterial loads of functionally AR-deficient (TFM)
males were significantly lower than in the AR+ male groups (*P<0.05, **P<0.01) and were
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equivalent to those in the female groups. In fact, the kidneys of most AR-deficient males were
sterile 2 wpi (below the limit of detection, indicated by the dotted lines).
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Abstract
Urinary tract infection (UTI), primarily caused by uropathogenic Escherichia coli (UPEC) is
a common, but dangerous disease in infants. Severe kidney infection serves as the primary cause
of acquired renal scarring, which can lead to long-term sequelae during adulthood, including
hypertension and chronic kidney disease. Advances in our knowledge of UTI have been
primarily discovered using a female mouse model. However, female mice show an inherent
resistance to severe ascending kidney infection. Consequently, there are currently no preclinical
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models to assess the consequences of recovery from pyelonephritis following antibiotic
treatment. We recently developed a male model of ascending infection where male C3H/HeN
mice develop robust pyelonephritis, renal abscesses, and evidence of fibrosis. Here, we
developed a ceftriaxone treatment strategy within our male model to more closely reflect the
clinical course of pyelonephritis. A 5-day ceftriaxone regimen administered to male mice at the
beginning of abscess development led to resolution of bladder and kidney infection. Despite
treatment, some infected mice displayed abscess immediately post-treatment, and a similar
fraction of mice developed gross renal scars by 28 days post-treatment. There was dramatic
evidence of fibrosis and ongoing inflammation in the scar, despite clearance of any viable
bacteria. While renal function was not impaired at 28 days post-treatment, animals developed
marked hydronephrosis and evidence of chronic kidney disease by 30 weeks of age. We present
the first effective treatment model to study the resolution of severe ascending pyelonephritis.
This model offers a platform to study the progression of kidney infection and resulting fibrosis,
allowing us to elucidate a more comprehensive understanding of the short and long-term effects
of UTI on kidney health.

Introduction
Urinary tract infection is a very common pediatric condition, regularly affecting infants and
young children in the first years of life (1-4). Ascension of uropathogens to the kidneys can lead
to pyelonephritis, which even with successful antibiotic treatment may carry long-term
repercussions for the patient, including the development of renal scarring, hypertension, and
eventual progression to end-stage renal disease (5-8). Ascending bacterial infection of the renal
parenchyma in humans and mice leads to severe tubulointerstitial inflammation (9-13). This
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innate inflammatory response, perhaps more than bacterial processes, may largely underlie renal
damage resulting from UTI, and is correlated with loss of functional renal tissue (scarring) and
the development of fibrosis (14-17). However, the mechanisms of how and if pyelonephritic
scars contribute to chronic kidney disease are unknown (18-20). Further, it is unclear if the
location, severity, or timing of renal fibrosis influences progression to chronic kidney disease.
The vague link between infection-related fibrosis and the development of renal disease has
been hindered largely by the lack of robust murine models of ascending upper-tract UTI in
immunocompetent hosts (9, 12, 13, 21, 22); while cystitis can be induced transurethrally in
females of many mouse strains, most are resistant to severe ascending infection of the kidneys
(9, 21-23). Previous studies have utilized direct injection of uropathogens into the kidneys, but
these models bypass ascension of the ureter (17, 24, 25). Further, existing studies have only
examined the generation of inflammation and fibrosis during ongoing, active infection or
following spontaneous resolution of infection (9, 12, 13, 26), while human patients would
typically receive antibiotic treatment, such as fluoroquinolones or cephalosporins, soon after the
onset of symptoms (27).
We previously found using a novel mini-surgical bladder inoculation technique that male
C3H/HeN mice, unlike females, develop severe pyelonephritis and renal abscesses following
ascending infection, and fail to spontaneously resolve UTI (9). Furthermore, infected males
developed fibrosis and progressive renal disease during later stages of infection (9). Here, we
extended this new preclinical model of UTI to test the efficacy of antibiotic treatment in severe
pyelonephritis and established renal abscesses, and to examine long-term sequelae of infection
following antimicrobial treatment.
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Materials and methods
Bacteria
Uropathogenic E. coli strain UTI89 was isolated from a patient with cystitis (28). For
surgical infections, bacteria were grown statically in Luria-Bertani (LB) broth for 16 h at 37°C.
The cultures were centrifuged for 10 min at 7,500 × g at 4°C before resuspension in sterile
phosphate-buffered saline (PBS) to a final density of 4 × 108 CFU/ml.

Introduction of murine UTI
A widely used female murine model of cystitis with transurethral inoculation via catheter has
been described in methodologic detail (29, 30), but this approach is technically precluded in male
animals. A recently developed surgical approach was used to initiate infection in male mice (9).
Eight-week-old male C3H/HeN mice (Harlan Laboratories, Indianapolis, IN) were maintained
under inhalation anesthesia with 3% isoflurane via vaporizer and nose cone. Anesthetized mice
were positioned supine, shaved, and the ventral abdomen was sterilized with 2% chlorhexidine
solution. A vertical, midline incision (2-3 mm in length) was made directly overlying the
bladder, first through the abdominal skin and then through the peritoneum. The bladder was
exposed, aseptically emptied, and punctured with a 30-gauge, 0.5-inch needle adapted to a 1-mL
tuberculin syringe containing the bacterial inoculum. Fifty microliters containing 1-2 × 107 CFU
was introduced to the bladder lumen over 10 s, the bladder was allowed to expand for a further
10 s, and the needle was then withdrawn. The peritoneum and the skin were closed with simple,
interrupted sutures, and the animal was awakened in fresh air.
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Ceftriaxone treatment
We modified previously described ceftriaxone treatment regimens used in female murine
models to clear UTI (31, 32). These dosing regimens result in circulating levels of drug similar to
those seen in patients treated with ceftriaxone (31, 32). At 120 h after surgical infection, male
C3H/HeN received 125 mg/kg ceftriaxone dissolved in sterile water by intraperitoneal injection.
Mock-treated animals received an equivalent volume of PBS. Mice received ip injection of
antibiotic or PBS every 12 h for 5 days, receiving 10 doses in total. Bladders and kidneys were
aseptically harvested 24 h after the last treatment to allow residual ceftriaxone to clear. For
chronic kidney function experiments, UPEC-infected animals that resolved infection
spontaneously before treatment or that failed to clear UTI following treatment (urine titers >104
CFU/mL) were excluded from analysis.

Tissue histopathology
Infected bladders and kidneys were bisected and fixed in 10% neutral buffered formalin for
24 h. Fixed tissues were embedded in paraffin, sectioned, and stained with hematoxylin and
eosin or with Gomori trichrome stain.

Determination of urine and tissue bacterial loads
Where indicated, we obtained post-infection, clean-catch urine samples using gentle
suprapubic pressure for serial dilution and plating to enumerate CFU/mL urine. At the indicated
time points, mice were euthanized via CO2 asphyxiation, and bladders and kidney pairs were
aseptically removed and homogenized in 1 ml or 0.800 ml sterile PBS, respectively. We plated
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serial dilutions of tissue homogenates on LB agar to enumerate bacterial loads. Where indicated,
infection in C3H/HeN mice was classified as “chronic” if all urine and endpoint bladder titers
contained >104 CFU/ml. “Resolved” mice demonstrated endpoint bladder burdens and at least
one urine time point <104 CFU/ml. Organ homogenates to be used for soluble cytokine analysis
were centrifuged at 15,000 × g for 5 min, and supernatants were stored at -80°C.

Blood and urine chemistry
Serum or urine was analyzed on the day of blood draw for blood urea nitrogen (BUN),
serum creatinine, or urine protein by standard autoanalyzer laboratory methods performed by
Department of Comparative Medicine core facility.

Inulin clearances
Inulin clearances were performed at 28 days post-treatment according to manufacturer
instructions (BioPal Inc., Worcester, MA).

Statistics
Organ bacterial loads and other numerical data were compared by the nonparametric MannWhitney U test. 2x2 comparisons were performed using the Fisher exact test. P values <0.05
were considered significant.
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Results
Infection and treatment model.
Female murine models have been successfully used to interrogate many questions on UTI
pathogenesis in the bladder, but females of most mouse rarely develop severe pyelonephritis or
renal abscess (9, 21-23). Even females in the C3H/HeN background (recognized to have
vesicoureteral reflux (21, 33)) that develop chronic pyelonephritis (without abscess) and are
treated with antibiotics maintain normal renal function and do not display evidence of renal scars
(22, 34). Because of this, there exist no optimal preclinical models of antibiotic-treated severe
pyelonephritis. Thus, we employed our mini-surgical infections of male mice to model the
resolution and sequelae of severe pyelonephritis. By 14 days post infection (dpi) with
uropathogenic Escherichia coli (UPEC) strain UTI89, greater than 90% of surgically infected
C3H/HeN males develop gross, bilateral renal abscess (9). In our efforts to model antibiotic
treatment, we first attempted multiple ceftriaxone dosing schemes starting 14 dpi in male
C3H/HeN mice; these strategies failed to effectively treat the advanced abscesses in kidneys
established by that time point (data not shown). Further, we felt it likely that patients would
more commonly present earlier in the course of pyelonephritis. We previously demonstrated that
abscesses develop rapidly in male C3H/HeN between 5 and 6 dpi, and are fully formed by 7 dpi
(Chapter 3). Therefore, we next elected to initiate intraperitoneal ceftriaxone (given every 12
hours [q12h] for 5 days) beginning 5 dpi, harvesting organs 24 h after the final dose of antibiotic
(i.e., 11 dpi; Figure 1A). Mini-surgical bladder inoculation in male C3H/HeN mice resulted in
robust bladder (Figure 1B) and kidney (Figure 1C) infection in both start-of-treatment controls
(5 dpi) and mock-treated animals. Ceftriaxone treatment significantly reduced the bladder
(Figure 1B; P<0.0001) and kidney (Figure 1C; P<0.0001) bacterial burdens compared to
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mock-treated animals. Antibiotic-treated mice resolved bacteriuria over the course of treatment
(Figure 1D). Ceftriaxone-treated mice continued to harbor 102-104 colony-forming units (CFU)
of UPEC in their bladders, despite resolving bacteriuria (Figure 1B and D); this is consistent
with prior reports of UPEC reservoirs residing within bladder tissue following antibiotic
treatment (9, 35, 36). The majority of treated mice completely resolved kidney infection
following antibiotic treatment (Figure 1C). Other treatment regimens beginning 5 dpi, including
increased ceftriaxone duration, dose, or frequency, did not further affect the organ bacterial
burden (data not shown) compared to this 5-day, q12h regimen.
Among mice sacrificed at the start of treatment (5 dpi), all of which had high kidney bacterial
burdens (Figure 1B), a minority (4 of 15, 27%) demonstrated gross abscess (Figure 2A),
matching our previous report at the same time point (9). All (10 of 10) infected, mock-treated
males displayed gross renal abscess formation by harvest 11 dpi (24 h post treatment completion;
Figure 2B). Thus, abscess development continued to progress during this six-day interval in the
absence of antibiotic treatment. However, ceftriaxone-treated mice displayed gross abscess
frequency 11 dpi (4 of 14, 29%) that was equivalent to 5-dpi start-of-treatment controls (Figure
2C). As noted above, these ceftriaxone-treated mice with evident abscess exhibited kidney
bacterial burdens at or near the limit of detection (Figure 1C), and did not have ongoing
bacteriuria (Figure 1D). These data suggest that ceftriaxone treatment arrested renal abscess
development and neutralized the burgeoning UPEC population within the renal parenchyma. As
expected, control mice (mock-infected with PBS and treated with ceftriaxone) displayed healthy
kidney architecture 24 h post treatment (Figure 2D).
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Convalescent outcomes in treated pyelonephritis.
While the majority of CRO-treated mice demonstrated sterile kidney titers 11 dpi, a small
proportion maintained low-titer UPEC burdens. Further, it was unclear if UPEC remaining in
the bladder post treatment would reemerge to continue infection. To specify outcomes of treated
pyelonephritis, we treated mice with CRO (5 days, q12h) beginning 5 dpi and quantified organ
bacterial burdens 4 wk post-treatment. All CRO-treated mice resolved renal and bladder
infection (Figure 3A; P=0.0007 and P=0.0003, respectively, vs mock-treated controls). No
CRO-treated mice displayed urine UPEC titers >104 CFU/mL after biweekly sampling, but a
small fraction had low-level colonization of the bladder (Figure 3A). Remarkably, gross renal
scars were found in several treated mice at necropsy 4 wk post infection (Figure 3B,
arrowheads). Affected kidneys demonstrated broad-based, “U”-shaped cortical scarring with
retraction of the renal parenchyma, matching the pathological descriptions of human
pyelonephritic scars (37). The fraction of mice displaying grossly visible renal scars 4 wk
following CRO treatment was similar to the fraction of mice demonstrating abscess at either start
of treatment (5 dpi) or 1 day post treatment (11 dpi) (Figure 3C). Collectively, these data
suggest that the tissue destruction associated with microscopic abscess formation is
pathologically associated with the ultimate development of renal scars.

Ceftriaxone treatment restores renal function at 1 month post treatment.
Individuals that develop acute pyelonephritis typically restore baseline renal function
following resolution of infection, and negative sequelae of resolved infection are not typically
seen until later in life (5-8, 38). We thus examined glomerular filtration rate (GFR) by inulin
clearance at 4 wk following treatment in mock-infected, ceftriaxone-treated mice; UPEC124

infected, mock-treated mice; and UPEC-infected, ceftriaxone-treated mice (Figure 4A). Not
surprisingly, chronically infected and untreated C3H/HeN males exhibited impaired renal
function (P=0.1143). Treatment with ceftriaxone normalized GFR in UPEC-infected mice to
levels equivalent to mock-infected, ceftriaxone-treated controls. Histopathologic analysis of
Gomori trichrome-stained kidney sections from ceftriaxone-treated mice that resolved infection
and lacked renal scars showed no increase in interstitial fibrosis compared to mock-infected,
ceftriaxone-treated controls, and had renal architecture similar to naïve, mock-treated animals
(Figure 4B, C). However, we found a consistent increase in glomerulosclerosis and
periglomerular fibrosis in UTI89-infected, ceftriaxone-treated animals (Figure 4C).

Renal scars, despite resolution of infection, harbor progressive inflammation.
Histopathological analysis of UPEC-infected, ceftriaxone-treated kidney sections by Gomori
trichrome staining revealed extensive cortical scars, with collagen deposition extending from the
renal capsule to the medulla (Figure 5A). Matching our gross observations, these cortical scars
appeared microscopically as strictures on the kidney. The renal capsule was dramatically
thickened overlying the scar (Figure 5B, C, black arrowheads). Fibrosis in these scars followed
patterns similar to those observed at earlier stages of abscess development 5 dpi and 11 dpi in
infected, ceftriaxone-treated mice (see Figure 2). No scars were observed in mock-infected,
ceftriaxone-treated animals. More striking was the presence of a cellular infiltrate within the
scar (Figure 5C, D), despite all tested animals in this group resolving renal infection (Figure
3A) and exhibiting sterile urine cultures. Collections of inflammatory cells (primarily
lymphocytes) and fibroblasts were embedded within the area of fibrosis (Figure 5D). These data
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suggest that the development and maturation of renal scars is an active process, even following
successful treatment of infection with antibiotics.

Pyelonephritic scarring leads to chronic kidney disease.
Children who develop renal scars following UTI are frequently followed into adulthood,
when signs of chronic kidney disease may manifest (5-8). Therefore, we surgically infected
male C3H/HeN mice with either PBS (mock) or UTI89 and treated with ceftriaxone before aging
to 30 weeks of age (i.e., 5 months post treatment). Infected and successfully treated mice
demonstrated slightly higher serum creatinine (Figure 6A), BUN (Figure 6B), and urine protein
(Figure 6C) at this time interval, but comparisons to mock-infected mice were not statistically
significant. However, one UPEC-infected mouse that developed bilateral scars displayed
extremely high serum creatinine and BUN, as well as urine protein (Figure 6A-C), suggesting it
had developed chronic kidney disease. No other UPEC-infected mice demonstrated gross scars
in this experiment.
Surprisingly, we found evidence of gross hydronephrosis in most infected males (Figure
7A). These animals had dilated ureters, and expansion of the renal pelvis was evident on
bisection of the kidneys. Histopathology confirmed these findings, with infected animals
displaying enlarged, dilated renal pelvis and calyces, flattening of the pelvic epithelia, atrophy
and thinning of the renal cortex, and expanded ureters (Figure 7B). These features were notably
absent in mock-infected animals (Figure 7C). While the frequency of gross scars was lower in
this chronic experiment, fibrotic scars were evident microscopically in UPEC-infected mice, but
not mock-infected controls (Figure 7D). These scars resembled those seen at 38 dpi (Figure 5),
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with areas of fibrosis and infiltrating inflammatory cells, and were commonly seen surrounding
the renal pelvis (Figure 7D).

Discussion
Here, we developed a novel antibiotic treatment model to study the resolution and sequelae
of severe upper-tract UTI. To do so, we took advantage of the surgical UTI model allowing
infection of male C3H/HeN mice, which develop nearly 100% penetrant renal abscess following
bladder inoculation with UPEC. While antibiotic treatment was not successful at later time
points (presumably because of progressed abscess, and consistent with clinical experience in
patients with established abscesses), ceftriaxone treatment at 5 dpi resulted in resolution of
infection. Surprisingly, a minority of infected, treated animals developed renal scars by 4 wk
post-treatment. These scars displayed ongoing inflammation despite infection resolution, and
animals that illustrated scars also demonstrated initial signs of chronic renal disease.
Our preclinical model of renal scarring following treatment of ascending UTI fills a
substantial gap in the field. No previously published reports examine outcomes in preclinical
models following antibiotic resolution of ascending infection. Instead, studies have been limited
to direct injection to the renal medulla (17, 24, 25) or examining renal damage following
spontaneous resolution or during active infection (9, 12, 13, 26). In part, progress in this arena
has been hampered by the inherent resistance of females in most mouse strains to pyelonephritis
(9, 22, 23, 39, 40). Our recent development of a male surgical model of UTI allowed us to take
advantage of male C3H susceptibility to pyelonephritis to probe questions on upper-tract UTI
pathogenesis (9). Here, we present a preclinical model using our male surgical technique which
more closely recapitulates the progression and resolution of human disease where mice develop
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ascending pyelonephritis, infection progresses to the beginning of abscess development, and
animals receive ceftriaxone.
Roughly one third of infected male C3H/HeN mice exhibited gross abscess at 5 dpi or
demonstrated sterile abscess post-treatment. Presumably, those mice that developed abscess
with associated necrosis of the renal parenchyma before and/or during ceftriaxone treatment
developed a scar in the area of resolved pyelonephritic abscess by 1 mpt, as a third of treated
mice demonstrated a renal scar at this time point. However, we currently have no data
definitively linking the anatomic locations of developing abscess and ultimate renal scars. Posttreatment abscesses demonstrated inflammation and tissue destruction similar to descriptions of
abscess 5 dpi (Figure 2, and Chapter 3), and inflammation persisted in the renal scar at later
time points post treatment (Figure 5), consistent with reports from human pathology (41). Thus,
we predict that the intense inflammation found in abscesses continues to evolve into the ongoing
inflammatory processes present within the renal scar. Further, we predict that the crux of scar
development lies in the inflammatory processes affecting the surrounding renal parenchyma.
Indeed, anti-inflammatory treatment modalities may be promising routes to circumvent the
development of chronic kidney disease, in conjunction or following antimicrobial therapy, to
lessen the degree of inflammation and/or impact of inflammatory modulators released from
pyelonephritic scars (18, 26, 42, 43).
Only a small percentage of humans presenting with upper-tract UTI develop renal scars
following resolution of acute infection; it is unclear why some individuals develop these scars
while others do not (38, 44, 45). Estimates of the risk of developing renal scaring after
pyelonephritis in children vary, but range between 8% and 40%, with a meta-analysis
approximating that 15% demonstrated evidence of scaring on follow up (38, 46). Our model of
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pyelonephritic scarring recapitulates this proportion, with 27% of mice developing renal scars.
Our previous data demonstrated that a window of 12 to 24 h (at days 5-6 post infection) could
make the difference between UPEC infection of the renal parenchyma with abscess formation or
limitation to the renal pelvis and calyces (Chapter 3). Clinical studies have shown that early and
aggressive antibiotic treatment minimizes the risk of renal scar formation (17, 47, 48); our
studies reinforce this point, suggesting that minor delays in the start of antimicrobial treatment
could substantially influence whether permanent renal damage occurs or if pyelonephritis
resolves without complication.
To our knowledge, there has been no demonstrated paradigm of UTI causing the
development of hydronephrosis. Several early studies did speculate that infection may cause an
increase in VUR, although the evidence for either cystitis promoting VUR or having no effect on
reflux is relatively weak (49-53). Conversely, individuals with hydronephrosis have increased
risk for UTI because of concurrent urodynamic abnormalities such as vesicoureteral reflux
(VUR) or urinary obstruction. The hydronephrosis evident long after antibiotic treatment of
infected mice was bilateral (Figure 7), suggesting augmented bilateral VUR, obstruction below
the bladder trigone (e.g., in the prostatic urethra), or bilateral defect in the ureterovesical junction
(the last of which seems unlikely). Further, treated males did not display evidence of
hydronephrosis at 4 weeks post-treatment, necessitating some disease progression between then
and 30 weeks of age when hydronephrosis was observed. While upper-tract UTI certainly raises
kidney damage, bladder and/or ureter remodeling following UTI may represent an under
recognized complication which contributes to long-term sequelae. This may prove to be a
vicious cycle in patients with urodynamic abnormalities, whom are already predisposed to UTI,
but whose urodynamics may regress with every additional UTI.
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Our initial experiments looking into the development of chronic kidney disease following
pyelonephritis produced promising, albeit inconclusive results. Overall, there was no difference
in markers of chronic kidney disease between mock- and UTI89-infected animals that received
ceftriaxone treatment. However, as noted above, these infection and treatment conditions
resulted in only a minority of animals developing gross renal scars, but the single animal that did
develop severe pyelonephritic scars had biochemical evidence of renal failure. More penetrant
or extensive scar formation may be required to concretely determine whether scar formation
associates strongly with chronic kidney disease. This could be potentially overcome by infecting
with a greater inoculum or initiating treatment at 6 or 7 dpi, when a larger majority of C3H/HeN
males have established gross abscess (9). Alternatively, most murine models of chronic kidney
disease require unilateral nephrectomy with injury or insult to the remaining kidney to induce
renal failure (54-57), and a similar unilateral or partial nephrectomy procedure could be
considered before infection and treatment in our model. Measurement of blood pressure will
help to correlate renal scars in mice with hypertension, which is more common as a sequela in
human pyelonephritis than CKD. Continued work along these lines will provide further
evidence to define the relationship between pyelonephritic scarring and chronic kidney disease.
In this report, we unveil a novel preclinical treatment model to study complications arising
from severe UTI. Susceptible hosts develop abscess following ascending UPEC infection, and
ultimately develop renal scars (which are not entirely quiescent) after successful antibiotic
treatment. This model promises to address the relationship between pyelonephritic scaring and
chronic kidney disease, as well as to uncover inflammatory factors and other host pathways
responsible for continued renal damage following infection resolution.
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Figures

Figure 1. Ceftriaxone treatment eliminates renal bacterial burden in male C3H/HeN. (A)
Male C3H/HeN mice were surgically infected with UTI89 or PBS and then treated with
ceftriaxone or PBS starting 5 dpi. Bladders (B) or kidneys (C) were aseptically homogenized
132

and plated to enumerate CFU 24 h after the last ceftriaxone injection. 5 dpi start-of-treatment
controls (triangles) were compared to mock-infected (diamonds), mock-treated (filled circles), or
ceftriaxone-treated (open circles) C3H/HeN. Data were compiled from three independent
experiments. (D) Male C3H/HeN were surgically infected with UTI89 and mock- (black circles)
or ceftriaxone-treated (grey circles) 5 dpi. Urine bacterial titers were followed during antibiotic
treatment. Solid lines connect corresponding urine time points from each individual mouse.
Dashed lines in all panels represent the limit of detection. Bars depict the geometric mean. (***
P<0.001)
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Figure 2. Ceftriaxone treated mice display renal abscess 11 dpi despite resolution of
infection. (A) Male C3H/HeN were mock-infected with PBS and treated with ceftriaxone at 5
dpi. Gomori trichrome staining reveals normal kidney architecture without the presence of
abscess 1 day after treatment. (B) All UTI89-infected C3H/HeN receiving PBS (mock)
treatment displayed abscess 1 day post treatment. (C) A small fraction (27%) of start-oftreatment controls sacrificed 5 dpi after surgical infection with UTI89 demonstrated renal
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abscess. (D) A minority (29%) of UTI89-infected, ceftriaxone treated male mice displayed
abscess by Gomori trichrome staining 1 day post treatment, despite resolution of renal infection
(Figure 1).
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Figure 3. Ceftriaxone treated mice clear infection and develop gross renal scars by 28 days
post-treatment. Male C3H/HeN were surgically infected with PBS or UTI89 and then treated
with PBS or ceftriaxone. (A) Bladders and kidneys were aseptically harvested, homogenized,
136

and CFU enumerated at 38 dpi (28 d post treatment). Ceftriaxone treatment significantly reduced
bacterial burden and resulted in sterile kidney titers 38 dpi (** P<0.01, *** P<0.001). (B)
Following autopsy, gross renal scars (white arrowheads) were observed in 27% of UPECinfected, ceftriaxone treated mice 38 dpi. A representative image of a scarred left kidney is
shown. (C) The percentage of animals developing abscess 5 dpi, 11 dpi following ceftriaxone
dosing (24 h post-treatment), or developing renal scars at 38 dpi (28 d post treatment) is
equivalent.
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Figure 4. Treated mice demonstrate healthy renal function 28 days post treatment.
Glomerular filtration rate was measured by inulin clearance at 38 dpi (28 d post treatment) in
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PBS-infected, ceftriaxone-treated; UPEC-infected, PBS-treated; and UPEC-infected,
ceftriaxone-treated mice (A). Gomori trichrome staining of renal cortex illustrates healthy
kidney histology in mock-infected mice which were treated with ceftriaxone (B). UPECinfected mice that had resolved pyelonephritis via ceftriaxone-treatment demonstrated minor
glomerular sclerosis, but displayed otherwise normal kidney architecture (C).
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Figure 5. Pyelonephritic scars demonstrate progressive inflammation. Gomori trichrome
staining of UPEC-infected mice 28 days post treatment demonstrated collagen deposition in
place of cortical tissue (A, B). This was accompanied by dramatic capsular thickening over the
scar (black arrowheads) and a cellular infiltrate (C). The inflammatory infiltrate appeared to be
mostly lymphocytic (D).

140

Figure 6. Ceftriaxone-treated mice do not develop markers of end-stage renal disease at 5
months post-treatment. PBS-infected mice (Mock) and UPEC-infected mice (CRO) were
treated with ceftriaxone 5 dpi and aged to 30 weeks. Serum was analyzed for creatinine (A) and
blood urea nitrogen (B). Most UPEC-infected mice demonstrated normal creatinine and BUN,
but one mouse that displayed bilateral scars demonstrated remarkably high creatinine and BUN.
Urine protein was also quantified (C).
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Figure 7. Infection resolution leaves residual hydronephrosis 5 months post-treatment.
Male C3H/HeN were treated with ceftriaxone 5 dpi and aged to 30 weeks to examine the
development of chronic kidney disease. The majority UPEC-infected, ceftriaxone-treated males
developed gross hydronephrosis with dilated ureters (A, black arrowheads). Histopathology of
Gomori trichrome stained sections confirmed hydronephrosis in UPEC-infected, ceftriaxonetreated mice (B), while PBS-infected, ceftriaxone-treated mice displayed normal kidney
architecture without noticeable hydronephrosis (C). UPEC-infected animals also displayed
evidence of fibrosis with active inflammation, despite resolution of infection (D).
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CHAPTER FIVE
CONCLUDING REMARKS AND FUTURE DIRECTIONS

Urinary tract infections (UTI) represent one of the most sex-discrepant infectious diseases in
humans, with wide disparity in sex-specific incidence of infection throughout the lifespan (1-3).
However, technical barriers in preclinical modeling have hampered progress in defining host and
microbial mechanisms responsible for the sex differences observed in UTI. This body of work
developed a novel murine model to interrogate sex discrepancies in UTI pathogenesis, concretely
defined a previously unrecognized hormonal influence on infection, and furthered our
understanding of bacterial and host mechanisms in pyelonephritis.
Unlike in female mice, routine transurethral catheterization of the bladder in male mice is
technically prohibitive. Previous murine models have utilized catheterization to instill
uropathogens into the urethra of male mice (4, 5). These models infect the murine prostate, but
fail to reproducibly infect the bladders and kidneys. Consequently, the lack of a tractable male
model of UTI has precluded a detailed examination of host and microbial mechanisms
underlying male urogenital infections and the sex discrepancies observed in UTI. In response to
this deficit, we developed a minimally invasive surgical technique that bypasses simple anatomic
differences between sexes to permit infection of the murine urinary tract in both male and female
hosts.
Using this model, we revealed the first evidence of an intracellular bacterial community
pathway utilized by uropathogenic Escherichia coli (UPEC) in male hosts. Compared with
females, males of two mouse strains displayed a striking predilection for severe and/or chronic
UTI. Further, C3H/HeN males developed more severe pyelonephritis, as well as 100% penetrant
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renal abscess (a complication that is rare in female mice). Within the abscess, UPEC formed a
dense nidus of intratubular, biofilm-like communities that were sheltered from surrounding
inflammatory cells by a fibrotic capsule likely built on tubular remnants. Male susceptibility to
severe UTI was mediated by testosterone exposure, and androgenized females likewise
developed more robust pyelonephritis and chronic cystitis. Testosterone or its derivatives
stimulated this phenotype via activation of the androgen receptor in both sexes.
We further used the male model as a platform for modeling severe pyelonephritis, addressing
questions about ascending abscess pathogenesis and the sequelae of severe infection following
antibiotic treatment. Of note, our mini-surgical model also consistently yields infection of the
prostate in males. Although not detailed here, we found preliminary evidence from gentamicin
protection assays of prostate tissue to suggest the existence of intracellular invasion and growth
by UPEC during murine prostatitis; additional microscopy studies are required to definitively
localize whether an intracellular niche exists. Collectively, these studies demonstrate the utility
of the male surgical model outside of sex-comparison research.

Androgen receptor influence on UTI susceptibility
The finding that androgen receptor (AR) activation augments UTI susceptibility opens up
vital avenues for further exploration. Primarily, this lends powerful genetic tools to scrutinize
the cell and/or tissue types responsible for androgen-mediated susceptibility to UTI. While our
data from lipopolysaccharide-insensitive C3H/HeJ mice suggests that mechanisms outside of
innate inflammation may be responsible for our phenotype, we can nonetheless pursue reciprocal
bone marrow transfers with Tfm mice to determine the relative contribution of the hematopoietic
versus epithelial/stromal compartment to androgen-mediated UTI susceptibility. Further, strains
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of C57BL/6 mice with floxed alleles of the AR are available to further dissect the specific
inflammatory cell lineages or bladder and/or kidney cell types responsible for our phenotype.
We thus propose to begin these experiments in the available C57BL/6 background while creating
analogous tools in C3H males because of the much more robust sex-discrepant and
pyelonephritis phenotypes.
This exploration parallels our quest to identify specific genetic pathways which contribute to
androgen sensitization. The exact mechanism which androgens elicit to provoke UTI
susceptibility is not clear. In an unbiased approach, we have initiated RNA-seq experiments
comparing the renal transcriptomes of acutely-infected wild-type males, wild-type females,
castrated males, re-androgenized castrated males, and androgenized females. While
androgenized hosts develop chronic cystitis more frequently than nonandrogenized hosts, it is
possible that this difference may be due to continual reseeding of the bladder from the infected
kidneys. Supporting this hypothesis, acute cystitis proceeds identically in male and female mice
of multiple mouse strains, while males consistently develop more robust pyelonephritis. Thus,
we postulate that androgen-induced susceptibility in the kidney is the primary driver of chronic
UTI in male hosts.
We have found preliminary data illustrating that androgenized hosts display remarkable
increases in the oxidative stress of the kidney prior to and during infection. Treatment with the
antioxidant, N-acetylcysteine, attenuated acute and chronic pyelonephritis in males, suggesting
that androgen-mediated increases in oxidative stress within the kidney may be a contributor to
UTI susceptibility. Genes that are known to control oxidation in the kidney, such as NADPH
oxidase, can be regulated by testosterone (6). Further exploration of this hypothesis by
quantifying expression of reactive oxygen species-producing enzymes in androgenized kidneys,
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testing UTI susceptibility in mice genetically deficient in these enzymes, and exploring
additional antioxidant therapeutics in male mice is warranted.
Open questions remain on the hormonal influences on UTI. While we find it unlikely that
perturbations in other hypothalamic-pituitary-gonadal axis hormones (including GnRH, FSH,
and LH) influence UTI susceptibility, these could be more thoroughly tested in turn. Our data
clearly suggest that estrogen depletion does not alter chronic outcome in female hosts, but the
effects of estradiol on acute pathogenesis in females remain incompletely defined. Indeed, there
are conflicting data showing increased UTI susceptibility from both estrogen depletion and
elevation in murine hosts, depending on the model used (7-9). Some of this may be explained in
part by concurrent fluctuations in testosterone, a previously unappreciated influence on UTI.
At a glance, our findings may appear to represent a stark contradiction – males develop more
severe UTI than females when infected via our surgical procedure, but nonandrogenized humans
(girls and women) account for the vast majority of UTI cases (2). In fact, the finding that
testosterone treatment in female mice perturbs UTI susceptibility extends this paradigm to
female populations as well. As detailed in previous chapters, distinct human populations support
our hypothesis. Notably, women with polycystic ovarian syndrome (PCOS), a hyperandrogenic
state, demonstrate increased incidence of UTI (10-12), and in preclinical models of PCOS, mice
overexpressing LH develop spontaneous pyelonephritis (13-16). The development of ascending
infection was attributed almost entirely to elevated estrogen in these models, but our data suggest
that increased testosterone may in fact be the culprit. These models have not been specifically
tested for UTI susceptibility with ascending infection models, and doing so would strengthen the
causality between hyperandrogenemia in PCOS and increased UTI incidence. The influence of
other hormonal perturbations in this model on UTI susceptibility could be ruled out via
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pharmacologic antagonism of specific signaling pathways (i.e., tamoxifen blockade of the
estrogen receptor).
Our hypothesis that the postnatal surge in testosterone in male infants increases UTI
susceptibility in this population has been detailed in previous chapters. To support this
hypothesis, we are collecting additional serum and urine samples from male infants less than 6
months of age with and without UTI to quantify testosterone levels. Female infants also display
a surge in hypothalamic-pituitary-gonadal axis hormones during the first 6 months of life with a
minor increase in circulating testosterone, albeit still dramatically less than the pubertal levels
seen in male infants (17). This burst of androgens may explain, in part, the increased risk of UTI
in male infants. Further, we have shown that antagonism of the AR with flutamide results in
modest attenuation of UTI in androgenized hosts. Androgen deprivation therapy with newer,
more effective nonsteroidal anti-androgens, such as bicalutamide or enzalutamide, could
represent a fruitful therapeutic avenue in certain cases of recalcitrant UTI. However, the efficacy
of these improved AR antagonists remains to be tested in murine models.

UPEC intratubular abscess communities
The discovery of UPEC intratubular communities within developing renal abscesses furthers
our understanding of bacterial pathogenesis during pyelonephritis. UPEC rapidly replicate in the
tubular lumina to form an intra-nephron nidus at the center of the nascent abscess. Notably,
these populations of bacteria are sheltered from phagocytic attack by the development of a
fibrotic capsule and the related inability of neutrophils to cross the tubular epithelia. Based on
the fact that C3H/HeJ succumb to disease between 3 and 7 dpi, a time frame when
immunocompetent mice develop renal abscess, we posit that this fibrosis surrounding the abscess
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communities protects the host from severe sepsis, albeit while also providing a privileged niche
for UPEC growth and persistence in the kidney. This fibrosis (as well as tubular occlusion) may
also limit antibiotic diffusion to the bacterial nidus during treatment. These bacteria already
appear to adopt a biofilm state, and it is well accepted that poor circulation and hypoxia present
in abscesses may limit antimicrobial efficacy (18). This combination of factors may underlie the
need for prolonged antibiotic treatment in pyelonephritis (19).
However, the details of the development and composition of the fibrotic capsule are
unknown. Previous reports have found that microinjection of UPEC into the tubular lumen
results in the development of mini-abscess, where bacteria are unable to cross the basal lamina.
Further, Melican and colleagues present some evidence that clotting may limit bacterial
dissemination from the colonized tubule (20). We suspect that the peritubular capsule is at least
partially composed of type IV collagen, plus coagulation components such as fibrin and
thrombin. Further investigation of the capsular components and pathways responsible for this
process could prove to be of therapeutic interest. We also observe death of tubular epithelial
cells surrounding the developing abscess community. The role of this cell death, as well as the
activity of peritubular myofibroblasts, in fibrosis development or abscess community formation
remains to be further explored.
During the development of the abscess communities, presumably before the development of
fibrosis, we still see the inability of inflammatory cells to access the growing UPEC
microcolonies within the tubular lumen. Thus, bacterial mechanisms may protect or prevent
neutrophil transmigration across the renal epithelia at these early time points. Known mutants in
UPEC immunomodulatory virulence factors, such as YbcL (21, 22), could be tested in C3H/HeN
males to examine this hypothesis. In this sense, the UPEC abscess community may be analogous
155

to the IBC, serving as a protected niche for UPEC while nearby inflammatory cells, which have
correctly located the bacterial colonies, cannot reach the biofilm community to phagocytose
bacteria (23). Indeed, similar bacterial mechanisms may facilitate this subversion of the innate
response in both pathways.
In the same vein, a single invasion event and robust expansion gives rise to the development
of a clonal IBC (24). We find that abscess communities were focal, interspersed between noncolonized, healthy areas of renal parenchyma. Further, the diseased area of the abscess follows a
papillary duct unit subtended by associated nephrons. Based on this, we speculate that a small,
founder population of UPEC gains access to the lower reaches of a collecting duct. Bacteria then
undergo robust clonal expansion to colonize multiple associated nephrons. This is further
supported by the precipitous rise of UPEC communities in the renal parenchyma between 5 and
6 dpi, while we see no evidence of bacteria in the tubules prior. We are currently exploring if
these bacterial populations are of clonal origin, and whether bottlenecks shape the UPEC
community during its establishment.
We have invested some time in searching for UPEC virulence factors which may specifically
increase pathogenicity in the male urogenital tract. We found that type 1 pili are essential for
abscess development in male C3H/HeN mice, demonstrating a previously unrecognized role for
type 1 pili in virulence within the kidney. This area also provides fertile ground for future
research, as type 1 pili may direct UPEC-epithelial or interbacterial interactions (25, 26). In
addition to testing other chaperone-usher pili encoded in UPEC genomes (27, 28), promising
targets include genes necessary for biofilm formation, such as those encoding curli or cellulose
production (28, 29). Utilizing androgenized females in conjunction with males would help
elucidate if the putative virulence factors were specifically altering infectivity in male-specific
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anatomic niches (e.g., the prostate or epididymis) or were necessary for severe pyelonephritis
and abscess development. Unbiased approaches, such as laser capture microdissection (30) of
the UPEC abscess community or other in vivo bacterial expression profiling, could aid in
developing additional targets.
It is notable that the urosepsis UPEC isolate CFT073 likewise causes ascending renal
abscesses in androgenized hosts. However, we observed that males began to succumb to
CFT073 infection at 2 wpi, presumably from sepsis, while we rarely saw death in UTI89infected males. In females, CFT073 is a far less fit bladder pathogen than UTI89, exhibiting
attenuation at both acute and chronic time points in the bladder and similar bacterial burdens in
the kidney (31). This suggests that CFT073 possesses an advantage in survival or propagation in
the androgenized kidney, or encodes tools that allow dissemination out of the abscess community
or colonized tubule. We have not yet detailed the histopathology of CFT073 abscess
communities in the kidney. The male surgical model could also be used to interrogate CFT073
virulence factors necessary for septic dissemination following renal ascension.

Pyelonephritic scarring
The modeling of the long-term sequelae of pyelonephritis has been limited by the inadequate
ability of current preclinical models to develop severe disease. We thus exploited our male
surgical technique to develop a ceftriaxone-treatment model of severe pyelonephritis. We found
that ceftriaxone-treated males develop renal scars and hydronephrosis following resolution of
infection. We are currently exploring if these events may compromise kidney function at distant
time points following pyelonephritis, and preliminary data indicate this to be true. Most
importantly, this model unveils almost limitless new directions to investigate post-pyelonephritic
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fibrosis, the development of hypertension and chronic kidney disease following upper-tract UTI,
and a potential causative relationship between UTI and hydronephrosis.
Most notable in our observations of the pyelonephritic scars was the accompaniment of
ongoing inflammation within and near regions of scar at 1 and 5 months post-resolution. This
finding suggests that a progressive process may contribute to the development of renal disease
rather than the cumulative loss of renal cortex from infection insult and consequential fibrosis.
Ongoing work will illuminate the specific cellular infiltrates present in these scars, their temporal
development beginning with active infection, local and systemic inflammatory mediators being
secreted, and the respective contributions of these infiltrates and mediators to scar development
and progressive renal disease (i.e., through depletion). These lymphoid aggregates present
within the scar demonstrated a resemblance to the previously described submucosal lymphoid
aggregates described in the bladder of mice and humans developing chronic UTI (32-34), and
similar processes may facilitate the recruitment of this ectopic lymphoid tissue during and
following UPEC infection regardless of the infected site. Links between UPEC-induced
inflammation and the inciting of host fibrosis pathways are currently being explored.
UPEC-infected male C3H/HeN treated with ceftriaxone and aged to 30 weeks surprisingly
developed nearly 100% penetrant hydronephrosis. This suggests that there is active remodeling
in the bladder, kidney, or both following recovery from UTI which gives rise to the development
of hydronephrosis. Other studies have not observed this phenotype in female mice that resolved
pyelonephritis, suggesting that hydronephrosis development may depend upon severe
pyelonephritis, renal abscess, or androgen effect. The cause of this phenotype and its potential
influence on future UTI susceptibility is an area that requires further investigation.
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We did not find convincing evidence of end-stage renal disease (ESRD) in UPEC-infected,
ceftriaxone-treated animals except in one mouse that developed severe, bilateral scarring. Given
that gross scarring develops in only a minority of animals, a greater infectious scarring insult
may be required to develop ESRD in this model. While we find it less likely, it may be that
pyelonephritic scarring does not lead to progressive ESRD, but rather just the functional loss of
cortical tissue to fibrosis which, when combined with unrelated renal insults later in life, sums to
potentiate ESRD. We plan to investigate other more common potential sequelae of scarring and
resolved pyelonephritis, such as hypertension. Further research investigating the mechanism of
pyelonephritic fibrosis and chronic kidney disease promises to help guide the development of
therapeutic modalities that block the fibrotic pathways or processes contributing to the
progression of this important disease.

Concluding remarks
In this work, we have developed a novel model to study sex differences in UTI pathogenesis.
We specified male-specific attributes driving more robust pyelonephritis and concurrently filled
a void in the field for modeling severe renal infection. In ascending renal abscesses, UPEC
organized into intratubular, biofilm communities which were protected from surrounding
inflammatory cells by peritubular fibrosis. The development of chronic UTI was dependent on
testosterone, and androgenization enhanced susceptibility to severe UTI in female mice,
signaling specifically through the androgen receptor. These findings give mechanistic insight
into why certain male and female patient populations have increased UTI susceptibility. While
this body of work significantly advances our knowledge of UTI pathogenesis, it also opens
countless new avenues for future exploration.
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Abstract
Urinary tract infections (UTIs), caused primarily by uropathogenic Escherichia coli
(UPEC), are among the most common bacterial infections in humans, costing billions of dollars
annually in medical expenses and causing significant morbidity with recurrent and chronic
disease. Many details of the molecular pathogenesis of UPEC UTI have been unveiled through
recent advances in a murine model of cystitis. Following ascension to the bladder, UPEC bind
and invade superficial facet cells of the uroepithelium via type 1 pili. Uropathogens are able to
evade innate cellular defenses, in part, by proceeding through an intracellular cascade in which
UPEC replicate within the facet cell cytoplasm, forming densely packed intracellular bacterial
communities (IBCs). Egress of filamentous bacteria from IBCs can initiate subsequent rounds
of IBC formation, thereby perpetuating acute infection. UPEC also invade the transitional
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epithelium, establishing latent, non-replicating reservoirs that resist antibiotic therapy and may
initiate same-strain recurrent infection. UPEC employ a variety of additional molecular
strategies to facilitate infection and to delay and subvert the host immune response. Finally,
novel therapeutic and preventive strategies such as anti-virulence compounds and vaccines may
be necessary to combat the growing threat of antimicrobial resistance.

Introduction
The human urinary tract is one of the most common sites for bacterial infection.
Uncomplicated urinary tract infections (UTIs) account for 8 to 14 million medical visits annually
and almost $4 billion in medical expenditures each year in the United States (1, 2). By the fourth
decade of life, half of all women report having had at least one UTI. Of those, 25% will
experience a second UTI and 3% will experience a third recurrence within six months after
treatment of the initial infection (3, 4). Molecular typing, including that by restriction fragment
length polymorphism analysis, suggests that up to two thirds of recurrent infections arise from
the same bacterial strain as that causing the initial infection (5). Same-strain recurrent infections
have been observed up to 3 years after an initial UTI (3, 6). As these chronic and recurrent UTIs
cause a substantial deterioration in patients’ quality of life (4, 7), a more thorough understanding
of the processes underlying the initiation and recurrence of these infections is needed.
Uropathogenic Escherichia coli (UPEC) cause up to 90% of all culture-confirmed UTIs
(3) and represent the leading cause of both community-acquired and healthcare-associated UTIs.
Other bacteria, including Staphylococcus saprophyticus, Klebsiella pneumoniae, Proteus
mirabilis, and Enterococcus spp., also cause community-acquired infections, while enterococci,
Pseudomonas and Candida are prominent among healthcare-associated infections. In most
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cases, UTI appears to develop along an ascending route, with urethral ascent following
periurethral colonization by the offending organism. These ascending uropathogens then
colonize the bladder epithelium using specific sets of virulence factors. Infection may be limited
to the bladder (cystitis) or ascend to the upper urinary tract causing pyelonephritis. Just as
multiple E. coli pathotypes (e.g., EHEC, ETEC, EAEC) cause distinct gastrointestinal diseases
(8), UPEC strains wield distinct repertoires of virulence determinants to cause disease and persist
in these separate niches within the urinary tract.
In order to successfully colonize the urinary tract, UPEC must circumvent formidable
host defense systems, which are mechanical, biochemical and immunologic in nature. The
traditional view holds that bacterial cystitis is considered an extracellular, self-limiting acute
infection. However, much of our current knowledge of the molecular intricacies of cystitis has
been more recently revealed using a robust murine model of ascending UTI. The pathogen
evades host defenses, in part, by proceeding through a well-documented intracellular cascade
where UPEC (and other uropathogens such as Klebsiella) adhere to and invade superficial
epithelial cells of the mammalian bladder (9-23). UPEC then rapidly replicate inside these host
cells, initially forming loose collections that subsequently coalesce into densely packed
intracellular bacterial communities (IBCs) (9). Murine and in vitro data have been corroborated
by detection of IBCs in human samples (24), suggesting that the IBC pathway observed in the
murine model recapitulates human cystitis.
In the following sections, though it is not feasible to exhaustively review decades of work
in UTI pathogenesis, we will detail some of the more recently revealed molecular attributes of
pathogen and host that define the conversation between these two entities and determine the
outcomes of encounter. Given our personal experience, many of these paradigms will be more
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relevant to cystitis than pyelonephritis. In addition, we will cover current clinical problems in
UTI and the prospects for novel therapeutics and preventives against these highly prevalent and
recurrent infections.

Epithelial Adhesion and Pili
Bacteria that fail to adhere to host tissues are unable to cause disease. This axiom is true
of many bacterial pathogens, especially those infecting epithelial surfaces, and has been clearly
demonstrated in the development of cystitis and pyelonephritis caused by UPEC, which produce
a variety of surface-associated structures that serve as adhesins (25). Most important for UTI,
UPEC may produce a variety of heteropolymeric, proteinaceous extracellular fiber-like
organelles, termed pili, that mediate adhesion to specific receptors on the uroepithelium. UPEC
genomes typically contain multiple discrete loci encoding highly resilient pili that are assembled
via the canonical chaperone/usher secretion pathway (25), as detailed elsewhere in this text. The
type 1 pilus mediates bacterial adherence to mannosylated uroplakin proteins on the luminal
surface of the bladder epithelium (26), while type P pili bind globoseries glycolipids found on
kidney epithelial surfaces (27). These fimbriae are critical for successful infection of the urinary
tract, with UPEC heavily relying on type 1 pili to colonize and invade the bladder epithelium (9,
18, 28-30).
The regulation of chaperone-usher pili by UPEC is a complex process. Type 1 pilus
expression from the fim operon is controlled on the genetic level by a process known as phase
variation, where bacteria may alternate between piliated (phase-ON) cells and nonpiliated
(phase-OFF) states. This is accomplished by inversion of a DNA segment, fimS, containing two
9-bp repeats flanking the fimA promoter (31, 32). During phase-ON, the orientation of fimS
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positions the fimA promoter toward the fim operon, allowing transcription of type 1 pili structural
subunits; transcription halts in the inverted phase-OFF position (33). Site-specific inversion of
fimS is catalyzed primarily by two linked recombinases, FimB and FimE (34), but may also be
mediated by other recombinases elsewhere on the chromosome (35). In addition, a complex
regulatory network controlling the modulation of expression of type 1 pili due to changing
environmental conditions is beginning to be elucidated. Many effectors, such as RpoS and
ppGpp, alter type 1 piliation by regulating expression and activity of recombinases (35-38).
Many other regulatory proteins also influence fim expression, including Lrp, CRP-cAMP, the
global regulator H-NS, and integration host factor (IHF) (39-42). Mechanisms may include a
proper DNA supercoiling of the switch site, aided by the binding and involvement of Lrp, IHF,
and H-NS to the region, consequently affecting the transcriptional promoter and/or the
recombination process (42-46). Additionally, the QseC sensor kinase and the transcriptional
regulator MarA have been recently identified as regulators of type 1 expression (47-49). These
emerging details suggest an intricate complexity of regulatory components that combine to
tightly control UPEC expression of this important urovirulence factor.

Toxins
UPEC may secrete a variety of toxins that damage host epithelia and promote
pathogenesis within the urinary tract. One of the earliest recognized toxins is the α-hemolysin,
named because it mediates eukaryotic cell lysis at high concentrations, an activity which might
promote the release of previously sequestered nutrients that can be used by UPEC during
infection. HlyA is distributed across a wide range of bacterial phyla and is a member of the
repeats-in-toxin (RTX) family of proteins. UPEC strains that express HlyA are associated with
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more extensive tissue damage and disease severity in the urinary tract (50-52). HlyA requires
activation of its protoxin form via post-translational acylation of two lysine residues. The
activated toxin disrupts eukaryotic cells by oligomerizing at higher toxin concentrations to form
pores in the host cell membrane in a calcium-dependent fashion, leading to cell lysis (53, 54).
Further, recent studies by Dhakal and Mulvey have shown that at sublytic levels, HlyA prompts
the degradation of host proteins (e.g., paxillin) involved in intercellular adhesion and host
cytoskeletal integrity (55). Thus, HlyA may be a primary bacterial effector driving the
exfoliation of superficial bladder epithelial cells that is observed early in the course of UPEC
infection (29). Additionally, as will be discussed further below, HlyA may inhibit
proinflammatory cytokine production by bladder epithelial cells (55). These findings
demonstrate interesting additions to the growing list of secondary functions of pore-forming
toxins and establish a more complete phenotypic basis for the high prevalence of HlyA carriage
among UPEC isolates.
Cytotoxic necrotizing factor 1 (CNF1) is expressed by ~ 40% of UPEC isolates and 30%
of E. coli from gastrointestinal pathotypes (56). Like HlyA, CNF1 may modulate a variety of
epithelial and leukocyte functions to propagate infection in the urinary tract. The toxin
constitutively activates small Rho GTPases such as Rac1, causing in vitro alterations that include
rearrangement of the actin cytoskeleton, enhanced uroepithelial membrane ruffling and uptake of
bacteria, uroepithelial cell apoptosis, and decreased PMN phagocytic activity (13, 57-61). The
implication is that in vivo, CNF1 likely promotes invasion of UPEC into the uroepithelium in
addition to suppressing phagocytic activity. Interestingly, CNF1 localizes to the bacterial
periplasm and appears to be delivered to host cells via the liberation of outer membrane vesicles,
which ferry the CNF1 as cargo to a fusion event with susceptible host cell membranes (61). Of
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note, HlyA or CNF1 mutants tested in multiple UPEC backgrounds generally remain virulent in
animal models of infection (52, 56, 62), suggesting that the mere encoding of these toxins by
UPEC is not essential for infection, but that spatiotemporal regulation of toxin expression and
secretion contributes to pathogenicity during UTI.
Several additional putative toxins are being uncovered that impact E. coli UTI. Mobley
and colleagues recently utilized in vivo induced antigen technology to identify a putative RTX
exoprotein, TosA, that is exclusively expressed in vivo during experimental UTI (63). The tosA
gene was found to be enriched among urinary isolates of E. coli compared to fecal isolates, and
tosA presence predicted successful colonization of the murine urinary tract (64), while deletion
of tosA led to significant attenuation in the urinary tract (63). Although the precise mechanism
remains unclear, TosA may enhance adherence in the kidneys and increase survival of UPEC in
invasive niches (65). As discussed below, other bacterial exoproteins, such as YbcL, may further
augment modulation of innate immunity when released during UPEC infection (66). Future
studies will undoubtedly specify novel UPEC toxins, further delineate their mechanisms of
action, and reveal the spatiotemporal regulation strategies that promote pathogenesis within the
urinary tract.

Other virulence determinants
A conserved mammalian host strategy during episodes of infection, including UTI,
involves exquisitely developed systems that sequester essential nutrients and thereby limit their
availability to bacterial pathogens. Notably, UPEC has evolved to reside in two distinct host
environments, namely the gastrointestinal and urinary tracts. Consequently, the pathogen’s
transition from the comparatively nutrient-rich gut involves substantial upregulation of nutrient
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acquisition systems to permit colonization of the nutritionally poor urinary tract (67).
Specifically, the acquisition of transition metals represents a constant battleground between a
bacterial pathogen and its mammalian host. Iron acquisition by UPEC has emerged as the
prototypical model for high-affinity nutrient uptake to combat host-mediated limitation.
UPEC and other extraintestinal pathogenic E. coli encode a greater variety of defined and
putative metal transporters compared to E. coli K-12 and other commensals (68). Further, E. coli
isolates causing UTI possess multiple functionally redundant systems mediating iron uptake,
suggesting that the urinary tract represents an iron-limiting environment during infection (68,
69). Many of these systems rely on bacterial secretion of low molecular weight Fe3+-chelating
molecules, known as siderophores, that serve to scavenge free and host protein-bound iron. Such
iron is then retrieved via receptors that facilitate transport of iron-siderophore complexes into the
bacterial cytoplasm. Four distinct siderophore systems have been characterized in UPEC:
yersiniabactin, aerobactin, enterobactin, and salmochelin (70). E. coli isolates expressing a
greater repertoire of siderophore systems may experience a fitness advantage during growth in
vivo and/or in human urine (71, 72). A recent report also suggests that siderophores may also
contribute to virulence by functions distinct from iron scavenging, demonstrating that
yersiniabactin can chelate Cu2+ and consequently increasing resistance to copper stress (73). In
addition to siderophores, UPEC employ a marked upregulation of direct heme receptors,
including ChuA and Hma, to scavenge free iron during UTI (67, 74).
UPEC has also developed mechanisms to counter the metabolic limitations of the urinary
tract. In response to experimental infection, the mouse uroepithelium increases expression of
genes involved in glucose import, likely to represent a response to increased cellular energy
requirements (67). Consequently, glucose may not represent the primary carbon source for
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UPEC in vivo, and UPEC may instead utilize short peptides and amino acids as carbon sources
during infection (75). Encoding of certain metabolic pathways allows UPEC to avoid stresses
introduced by other metabolite-limiting systems evolved by mammalian hosts. For example,
activity of the indoleamine 2,3-dioxygenase (IDO) pathway limits tryptophan availability for
many human pathogens; because UPEC is able to synthesize endogenous tryptophan,
upregulation of IDO during UTI does not limit UPEC growth (76).
As with other encapsulated bacteria, the elaboration of capsular polysaccharides by E.
coli has been shown to inhibit phagocytosis and increase serum resistance (77, 78). Many UPEC
isolates express group II capsules, primarily the K1 polysaccharide, a linear α2-8-linked sialic
acid homopolymer (50, 79) that is shared by Neisseria meningitidis group B. Earlier studies
indicated that capsule-deficient UPEC mutants have reduced fitness during experimental UTI,
including deficiencies in both the upper and lower urinary tract, though specific deficits in the
pathogenic cascade had not been investigated (80-82). More recent data demonstrate that
capsule-deficient UPEC mutants are hindered in their ability to aggregate and form IBCs,
suggesting that K1 capsular polysaccharide contributes to the coalescence and organization of
these IBCs within superficial facet cells, perhaps as a key constituent of the IBC matrix (83).
This lack of biofilm-like intracellular aggregation by capsule-deficient mutants may also leave
the bacteria more susceptible to neutrophil attack, soluble immune mediators, or antibiotics (83).
It is currently unclear whether other capsular serotypes might contribute to IBC formation in a
similar fashion and how UPEC capsule specifically promotes virulence within other urinary tract
niches.
Additional factors promoting UPEC biofilm properties in vitro may also prove to be
important in vivo during IBC formation. A comprehensive screen of UPEC transposon mutants
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identified a variety of novel effectors involve necessary for in vitro biofilm growth. Mutations in
a subset of these effectors resulted in attenuation during murine UTI, with significantly
decreased capacity for IBC formation (84).

Invasion of UPEC into the uroepithelium
The most current paradigm for the progression of cystitis involves invasion of UPEC (or
other uropathogens, such as Klebsiella species) into superficial bladder epithelial cells (9-23, 8587). Invasion of UPEC into kidney epithelial cells has also been demonstrated (88, 89), but the
ramifications of this event for disease progression are not as clear as in cystitis. In addition to
adhesive pili, UPEC invasion into superficial bladder epithelial cells involves numerous host
factors (Table 1). In many cases, these invasion events result in initial confinement of
internalized UPEC within a membrane-bound compartment. Fusiform vesicles, small “chunks”
of uroplakin-expressing apical epithelium, normally cycle into and out of the apical membrane to
regulate bladder surface area during the accumulation of urine (11). Pharmacological
interference with these host processes has been shown to significantly affect numbers of
intracellular UPEC (Table 1), suggesting that the invasion process, at its core, may be a
reflection of UPEC co-opting this normal membrane cycling (discussed later). The use of such
agents may therefore represent a novel therapeutic approach to reduce the intracellular bacterial
burden as a means to prevent or attenuate UTI.
To date, no bacterial effectors that modulate the host specifically to enhance UPEC
invasion of epithelial cells have been identified. The FimH adhesin of the type 1 pilus is both
necessary and sufficient for internalization (17, 23, 90). Beyond the membrane-bound
intracellular UPEC that may recycle to the surface, a small percentage of internalized UPEC gain
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access to the cytoplasm. It is unclear whether this cytoplasmic niche is attained by previously
membrane-bound organisms (through a yet-undefined mechanism), or if these cytoplasmic
bacteria have followed an alternative cell-entry pathway. Growth of UPEC within the cytoplasm
of cultured bladder epithelial cells occurs when detergents are added post-invasion (14),
suggesting that escape from the membrane-bound compartment is sufficient to facilitate
intracellular replication. This cytoplasmically located subpopulation of UPEC represents the
ultimate source for ongoing colonization, robust bacterial expansion within IBCs, and eventual
bacterial persistence within the uroepithelium.

Intracellular lifestyle of UPEC during cystitis
Time-lapse fluorescence microscopy of live, explanted infected murine bladders revealed
that UPEC proceed through a complex developmental and differentiation pathway during
experimental cystitis, multiplying in number and evading host immune effectors by establishing
a niche within superficial bladder epithelial cells (91). The developmental pathway includes two
independent branches that are distinguished by different patterns of morphological
differentiation. At the earliest stage, all of the bacteria exist in a standard bacillary shape (ca. 1
µm × 3 µm). These early-stage UPEC double every 30 minutes within loosely associated IBCs
(Figure 1). The majority of the bacteria within an IBC mature through the first differentiation
branch and synchronously divide with a shorter cell length to yield daughter cells that appear
more coccoid (ca. 1 µm × 1 µm). This coccoid shape allows for more efficient utilization of the
intracellular space than the bacillary shape, by approximately 2 orders of magnitude. It has been
estimated that ~104-105 organisms occupy the cytoplasm of the infected superficial facet cell, or
pod (9). As a consequence of the coccoid shape, the architecture of the UPEC community
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becomes more spherical (91, 92) (Figure 1). Physiological changes accompany these
morphological changes, as evidenced by a reduction in growth rate (increase in doubling time to
~45 minutes). As the size of the IBC approaches the capacity of the pod, the coccoid-shaped
bacteria at the periphery of the IBC regain a bacillary shape and become highly motile (Figure
1). This stage is typically associated with apoptosis and cell death (29, 93-95), providing
disruptions in the cell membrane to permit escape of motile UPEC (Figure 1) that subsequently
attach to naïve epithelial cells or leave the host through micturition.
Meanwhile, a minority of the early-stage intracellular population proceeds through a
second differentiation branch that results in the formation of non-septate filamentous bacteria
(up to 70 µm in length), associated with expression of the cell division inhibitor SulA (91, 96).
These filamentous morphotypes egress along with bacillary-shaped bacteria and attach to the
luminal surface of the bladder epithelium. Cell division is restored once these filamentous
UPEC are extracellular, and they ultimately produce daughter cells of normal bacillary length
that remain adherent to the bladder surface (91). The advantages of this second morphotype
during fluxing include increased resistance of the filamentous bacteria to neutrophil and
macrophage phagocytosis (96, 97). The observation that each intracellular community arises
from a single progenitor cell (98) suggests that the signals directing these dual, parallel
developmental programs are derived from the host microenvironment.
Following egress, attachment to naïve superficial epithelial cells can initiate subsequent
rounds of IBC formation that perpetuate the infection. During experimental UTI in the murine
model, the first round of IBC formation proceeds with remarkable synchrony. With typical
inocula of UPEC during experimental murine cystitis (~107 CFU), several hundred IBCs develop
during each cycle. Because human UTI arises from a presumably lower inoculum, cystitis could
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be initiated by a single bacterium that gains access to the bladder epithelial cell cytoplasm. With
each round of IBC formation, there is significant discharge of bacteria into the urine (bacteriuria)
through egress, but the intracellular amplification of UPEC leads to the propagation of infection.
Apoptosis of superficial epithelial cells as a consequence of infection results in the
release of cellular debris, including harbored IBCs (24), into the urine. Later during infection,
this exfoliation eventually involves most or all of the superficial epithelial layer, exposing the
underlying transitional epithelium. Unlike other epithelial layers of the body that completely
turn over within days, normal bladder epithelium may require 6 months for turnover of the
superficial bladder epithelial cells (99). Exfoliation that follows UPEC infection in mice is
accompanied by dramatically activated differentiation machinery, so that a new superficial layer
is regenerated within days (29, 100). Although one would imagine that exfoliation of the
superficial facet cells (particularly those containing IBCs) might attenuate the acute infection, it
conversely sets the stage for the establishment of a quiescent intracellular reservoir (QIR) that
has characteristics of a latent infection. In contrast to the invasion of superficial facet cells,
where a small proportion of invaded bacteria become free within the cytoplasm, invasion into the
transitional cells results in bacteria within a membrane-bound compartment (101) that does not
support growth (91). The QIR remains intact following differentiation of the transitional cells
into new superficial facet cells. Following experimental cystitis in mice, the QIRs are observed
for months (85), are resistant to systemic antibiotic therapy, and can serve as the source for
recurrent UTIs (102). Although exfoliated pods and filamentous bacteria are readily identifiable
in the urine during UTI in humans, direct evidence of QIR formation in humans is lacking. The
use of fluorescent 16s RNA probes was unsuccessful in the identification of QIR within biopsies
of children with recurrent UTI (103). This study highlights the need for new approaches to
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identify QIRs in human samples, given the suspected few numbers of QIRs and the apparently
low metabolic and growth activity of these chronically resident bacteria.
The relevance of the IBC cascade, defined in the murine model, to human cystitis has
been validated through multiple independent lines of investigation. The first approach involved
the analysis of five different murine host strains (C57BL/6, CBA/J, FVB/NJ, C3H/HeN, and
C3H/HeJ) and four clinical isolates of UPEC (from distinct patients with the clinical syndromes
of acute cystitis, recurrent cystitis, pyelonephritis, and asymptomatic bacteriuria); the
observation that multiple human UPEC isolates and multiple murine genetic backgrounds
supported IBC formation indicates that this developmental pathway is not limited to a single
UPEC/host pair (104). A second and more convincing approach involved the detection of
exfoliated epithelial cells bearing IBCs in urine specimens from women seeking treatment for
UTI (24). These authors also observed filamentous bacteria in 41% of these urine samples,
demonstrating that bacterial filamentation occurs commonly during human cystitis. Third, in
addition to E. coli UTIs, filamentous bacteria were observed in urine samples from women
infected with Enterobacter aerogenes, Klebsiella pneumoniae, or Proteus mirabilis (24),
indicating that the second branch of the developmental pathway is common to multiple Gramnegative bacteria causing disease in the urinary tract. Finally, upon infection with pools of
genetically “bar-coded” isogenic UPEC strains, a significant decrease in the diversity of the
UPEC population was observed in temporal association with the second round of IBC formation
(98). The intracellular paradigm predicts such “bottlenecks” in the diversity of organisms
colonizing the bladder (due to the relatively few numbers of epithelial cells that house
developing IBCs; Figure 1), while exclusive luminal infection would not be characterized by
these bottlenecks. Taken together, these data indicate that the paradigm arising from UPEC
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infections of mice can likely be translated to the human condition and to infections caused by
other uropathogenic bacteria.

Chronic cystitis
The introduction of bacteria into the urinary tract of susceptible murine host strains can
also result in a long-term chronic infection characterized by ongoing high bacterial loads and
inflammation, including robust neutrophil infiltration (105). This phenotype appears to arise as
the result of an early immune checkpoint involving multiple cytokines (e.g. IL-5, IL-6,
granulocyte colony-stimulating factor, keratinocyte-derived cytokine) (105). Of interest,
development of this chronic active cystitis could be prevented by the prior treatment with the
anti-inflammatory agent, dexamethasone (105). This model provides a tool to elucidate the
natural history of UTI and mechanisms that might underlie chronic UTIs.

Immune response and evasion
Innate immunity, particularly those responses initiated by Toll-like receptor 4 (TLR4)
recognition of the lipopolysaccharide (LPS) of Gram-negative bacteria, has attracted the vast
majority of attention paid to the immune defenses of the mammalian bladder. Early observations
that the murine C3H/HeJ background was more susceptible to UTI (as measured by recoverable
colony-forming units from bladder and kidneys) were followed by identification of a mutation in
the Tlr4 gene (106, 107). Stimulation of TLR4 activates the classic NF-κB pathway via the
adaptor MyD88, IL receptor-associated kinase (IRAK), and other kinases in the host epithelia
and immune effector cells, leading to expression of IL-6 and IL-8, which are measurable in the
urine of mice and humans with UTI (108, 109). However, a second pathway activated by TLR4
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in bladder epithelia also results in IL-6 and IL-8 expression (110). In this model, LPS
stimulation of TLR4 triggers an influx of Ca2+ into the intracellular space, followed by an
increase in cyclic AMP (cAMP) levels. The cAMP response element binding (CREB) protein
then becomes phosphorylated, resulting in additive promotion of the transcription of both
cytokines. Data from selective blockade of these signaling cascades suggests that epithelial
secretion of IL-6 may be even faster via cAMP/CREB than through the canonical TLR pathway
(110).
On the basis of these and other observations, and given that IL-8 is a recognized
chemoattractant for neutrophils, the defect in UTI resistance seen in C3H/HeJ (i.e., functionally
TLR4-deficient) mice has been attributed primarily to a failure to recruit neutrophils to the
bladder upon UPEC infection (111). However, recent data suggest that TLR4 may mediate host
defense mechanisms beyond the recruitment of immune cells. Epithelial invasion studies in
C3H/HeJ mice revealed a 10-fold increase in intracellular bacteria 1 h post infection, compared
with C3H/HeN (wild-type TLR4) mice (112). This phenotype was found to relate to two
additional TLR4-stimulated processes. First, intracellular cAMP inhibited Rac-1, a host protein
necessary for cytoskeletal rearrangements that accompany bacterial invasion, thus potentially
rendering superficial bladder epithelial cells less receptive to bacterial internalization. Second,
bladder epithelial cells can actively expel nascently invaded bacteria in association with the
normal exocytosis of fusiform vesicles that accompanies bladder distension. Expulsion via this
membrane-cycling mechanism is dependent on TLR4, cAMP, Rab27b, and caveolin-1 (11, 85,
112, 113).
Bacterial products beyond LPS may also stimulate TLR4 and other TLRs expressed on the
uroepithelium and/or resident immune effector cells of the urinary tract. Both type 1 and P
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fimbriae appear to stimulate TLR4, via FimH and a ceramide linkage of globoside receptors,
respectively (114-117). TLR5 stimulation, responding to bacterial flagellin, also contributes to
acute inflammation, as mice lacking TLR5 experience more robust infections of the bladder and
kidneys (118). Human ureter epithelial cells grown in vitro showed a response to flagellin but
not to LPS, suggesting that TLR5 may be important during the initial inflammatory response
(119). Finally, mice lacking TLR11 (associated with a pseudogene in humans) were shown to be
more prone to upper tract UTI (120).
Neutrophils play a critical role in controlling UPEC UTI; peripheral neutrophil depletion
of C3H/HeN mice resulted in a drastic impairment in clearance of UTI, with higher bladder and
kidney bacterial loads than in the TLR4-deficient C3H/HeJ background (where PMN response is
diminished and delayed) (121). This suggests that other mediators also shape the timing and
extent of the PMN response to infection in the mammalian bladder. UPEC infection was
demonstrated to induce the secretion of granulocyte colony-stimulating factor (gCSF) in the
bladder, and antibody-mediated depletion of this cytokine reduced PMN influx following UPEC
infection (122). Similarly, plasminogen activator inhibitor type 1 (PAI-1) influences cell
migration through its effects on integrin binding; upon UPEC infection of mice lacking PAI-1,
kidneys bore significantly higher bacterial burdens and fewer PMN infiltrates than wild-type
counterparts did (123). The secretion of a number of soluble antibacterial compounds into the
urinary tract is also induced during infection. The human cathelicidin LL-37, a short
antibacterial peptide, is detectable in the urine during human cystitis, and mice deficient in its
ortholog (CRAMP) demonstrate increased susceptibility to pyelonephritis (124), though its
impact on cystitis remains incompletely explored. Multiple members of the defensin class of
antimicrobial peptides are also produced locally during UTI, and the participation of these
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molecules in the host-pathogen conversation remains a fertile area for study. Of note, UPEC
also elicit the production of nitric oxide via induction of the iNOS gene (100), although the
impact of this on infection outcome is questionable, as mice deficient in iNOS have not shown
increased susceptibility to UTI (125, 126).
Despite this substantial provocation of the innate immune system during infection, UPEC
is able to persist in the urinary tract, withstanding mechanical defenses, acute immune insults and
chronic immune surveillance. Early in infection UPEC must survive a highly inflammatory
soluble and cellular response, specifically a robust influx of neutrophils mediated by local
secretion of multiple cytokines and chemoattractants. A growing body of data demonstrates that
UPEC employs a variety of strategies to delay, dampen, attenuate, and subvert these acute host
responses to infection.
As detailed above, multiple steps in the pathogenic cascade of cystitis (e.g., epithelial
invasion, IBC formation, and bacterial filamentation) illuminate critical UPEC strategies for
immune evasion. Of primary importance, the intracellular niche provides a haven for bacterial
multiplication, subverting PMN phagocytic activity. By video microscopy, PMNs can be
observed readily engulfing luminal bacilli within hours of murine infection. Meanwhile, UPEC
that have successfully invaded (and are replicating within epithelial cells) are sheltered from this
attack; PMNs are clearly able to locate infected superficial epithelial cells but cannot access the
expanding bacterial community (127). Mature IBCs also yield a population of organisms that
assume a filamentous morphology, subsequently traversing the luminal surface to initiate
additional rounds of IBC formation in naïve epithelial cells. Again, during this time of
transition, bacillary forms of UPEC are readily engulfed, while the filamentous bacteria resist
phagocytosis, even when coming in direct contact with PMNs and macrophages (96, 97). Egress
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of bacteria from mature IBCs coincides with an enrichment of filamentous forms within the
bladder lumen, consistent with a selection process arises where bacillary forms are preferentially
taken up by host phagocytes (127); this preferential engulfment is also supported by in vitro flow
cytometry studies (97). Confirming that a true conversation is taking place, filamentation was
not observed in TLR4-deficient backgrounds and was found to be induced in vitro by exposure
of bacillary UPEC to LPS-activated macrophages (97, 127).
In a related arena, several recent studies suggest that UPEC, unlike laboratory or
commensal strains of E. coli, can partially suppress epithelial inflammatory responses. UPEC
stabilize IκB, suppressing NF-κB activity in association with increased bladder epithelial cell
apoptosis upon exposure to UPEC (128). Further, multiple UPEC isolates elicit lower levels of
IL-6 and IL-8 from uroepithelial cells and are able to block secretion of these cytokines upon coinoculation with known NF-κB stimuli (129, 130). Genes involved in LPS biosynthesis are also
important for this phenotype, suggesting that LPS modifications imparting a less stringent
inflammatory phenotype may underlie the nonstimulatory properties of UPEC (130, 131). In
addition, lack of the OMP chaperone SurA abolishes the immunosuppressive phenotype (130);
reduced levels of the SurA-dependent LPS transport protein LptD may alter the presentation of
potential nonstimulatory LPS (132).
However, LPS differences alone do not account for cytokine suppression (133), and it is
likely that other mechanisms and UPEC effectors also contribute to suppressing cytokine
secretion. For example, NF-κB signaling may be inhibited by sublytic concentrations of αhemolysin (55, 134). Also, a minority of UPEC, including the pyelonephritis/urosepsis strain
CFT073, encode a Toll/IL-1 receptor (TIR) domain-containing protein, termed TcpC, that
interacts with the host adaptor MyD88 to inhibit TLR signaling (135). TcpC disruption was
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associated with decreased bacterial burden in the kidneys and a reduction in histologically
evident renal damage, signifying the importance of this protein during pyelonephritis. Further
study of additional signaling pathways that rely on TIR domain-containing proteins (e.g., the
TRIF and IL-6/IL-1 signaling cascades) revealed that TcpC also regulated these pathways
independent of MyD88, suggesting that TcpC may impact pathogenesis in a broader way (136).
Finally, the SisA and SisB proteins, homologues of the immunomodulatory protein ShiA from
Shigella flexneri, are found in CFT073 and have been recently implicated in immune modulation
during UTI (137).
In addition to suppressing proinflammatory cytokine production, UPEC is also able to
resist and modulate neutrophil functions (138). UPEC strains are able to resist phagocytic killing
in comparison to non-pathogenic E. coli isolates, down-regulating expression of PMN genes
involved in neutrophil chemotaxis, proinflammatory signaling, adhesion, and migration (138).
UPEC isolates also elicit reduced bladder PMN influx in vivo and attenuate transepithelial PMN
migration in an in vitro model (66, 138). UPEC have been shown to induce a number of antiinflammatory molecules in neutrophils, including indoleamine 2,3-dioxygenase (IDO) (138).
IDO induction within PMNs and uroepithelial cells during experimental cystitis resulted in
dampened PMN influx, correlated with increased survival of extracellular UPEC (76).
As noted above, UPEC employ the toxins HlyA and CNF1 to neutralize the phagocytic
activity of PMNs (60-62, 139-141). A newly identified UPEC effector, termed YbcL, has been
shown to inhibit transepithelial migration of human neutrophils via a distinct but as yet
incompletely defined mechanism. This effector localizes initially to the bacterial periplasm and
is subsequently liberated, suppressing PMN migration in both in vivo and in vitro models (66).
Interestingly, YbcL homologs present in laboratory or commensal E. coli isolates are unable to
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suppress PMN migration due to a single amino acid mutation, while most UPEC strains encode
the suppressive YbcL variant (66). In sum, these anti-neutrophil strategies of UPEC appear
important in delaying PMN influx and avoiding phagocytosis at the earliest stages of infection,
allowing the pathogen a window of opportunity in which to establish its protected intraepithelial
niche.

Host genetic susceptibility determinants
In addition to many bacterial determinants, there are host traits that contribute to disease
susceptibility, severity and progression. The strong gender bias in the frequency of UTI has
traditionally been attributed to the anatomical differences between sexes (distance from anus to
urethral opening, length of the urethra, and permissiveness of the vaginal/perineal
microenvironment). Dysfunctional voiding and other urodynamic abnormalities are associated
with increased susceptibility to UTI in children (142), and pregnancy also predisposes to UTI.
However, it is likely that sex differences and inter-individual differences in susceptibility
represent phenotypes that are more complicated than these simple reasons explain. Along these
lines, multiple efforts to define host genetic determinants of susceptibility to UTI have been
modestly successful. Given the observations outlined in the foregoing section, attention in this
realm has been focused on host innate immune genes. However, it has also become clear that
susceptibility is both polygenic and environmental, and that genetic determinants of distinct
clinical syndromes (asymptomatic bacteriuria, cystitis, and pyelonephritis) must be pursued
independently.
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P blood group.
Globoseries glycolipids, which serve as receptors for the UPEC P pilus adhesin PapG,
also represent P blood group antigens. Early work indicated that individuals expressing the P1
antigen have higher susceptibility to pyelonephritis (143).

TLR4.
As noted above, Toll-like receptors, including TLR4, play important roles in the early
detection of the arrival of pathogenic bacteria in the bladder, initiating pro-inflammatory
signaling that culminates in the arrival of neutrophils and other immune cells to the site of
infection. Children that present with asymptomatic bacteriuria are more likely to exhibit lower
levels of TLR4 on neutrophils than those from control children (144); in addition, these children
demonstrate accompanying differences in the expression of certain adaptor proteins in the TLR
signaling pathways (144). Polymorphisms in the Tlr4 promoter region were found to correlate
with the magnitude of neutrophil influx into the urinary tract of adults that received experimental
UTI with a strain of E. coli associated with asymptomatic bacteriuria (145).

Interferon regulatory factor 3.
Irf3 is a cytoplasmic protein that, upon ligation of TLRs or other surface receptors, binds
a cytoplasmic partner and translocates into the nucleus, where it upregulates expression of type 1
interferons and other genes. Though this pathway is most tightly linked to immune responses to
viral pathogens, mice deficient in production of Irf3 exhibit increased frequency of
pyelonephritis, renal abscesses and urosepsis upon transurethral inoculation (146). In humans,
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those carrying Irf3 promoter polymorphisms demonstrated reduced innate immune responses to
an asymptomatic bacteriuria strain of E. coli (145).

Interleukin-8.
IL-8, whose gene is a target of TLR- and IL-1-stimulated NF-κB signaling, is a key
mediator of neutrophil recruitment in response to bacterial cystitis, and genetic alterations related
to IL-8 and its signaling have been linked to susceptibility to pyelonephritis. First,
polymorphisms in the IL-8 gene itself were associated with pyelonephritis (147). In addition,
low CXCR1 (IL-8 receptor) expression levels resulting from mutations or polymorphisms are
correlated with acute and recurrent pyelonephritis (148, 149). Mice deficient in the related
chemokine receptor CXCR2 (which recognizes IL-8 and other stimuli) demonstrate increased
susceptibility to experimental UTI, renal scarring and urosepsis (150, 151).

Antimicrobial resistance and anti-virulence strategies
Over the past two decades, the management of extraintestinal E. coli and UPEC
infections has been complicated by the emergence and expansion of antibiotic resistance (152).
Resistance to first-line antibiotics has resulted in delays in appropriate therapy and an increase in
morbidity and mortality (153). Indeed, 20-45% of UPEC isolates are now resistant to first-line
therapy, according to surveillance studies of Europe and North and South America (154).
Particularly alarming is the rapid development of resistance to β-lactam antibiotics among
uropathogens due to the emergence of novel β-lactamases, including extended-spectrum βlactamases (such as CTX-M) (152, 155, 156), metallo-β-lactamases (NDM-1) (157-160), and
carbapenemase (KPC) (161).
186

In cystitis, steps inherent to the pathogenicity cascade (e.g., the intracellular location and
biofilm-like properties of bacterial communities, and the apparent quiescence of chronically
resident reservoir bacteria) may further confound treatment of resistant UTIs, providing
organisms with niches where antibiotic penetrance and/or efficacy is insufficient. Novel
strategies targeting the mechanisms of pathogenesis may provide an approach that limits
antimicrobial resistance by imparting decreased selective pressure on uropathogens. Moreover,
such anti-virulence strategies could limit the impact on the microbiota and lessen off-target
effects of therapy. Recently, compounds blocking FimH interaction with the bladder epithelium,
termed mannosides, prevent UPEC adherence, invasion, and IBC formation in the bladder (162,
163). When dosed orally, mannosides were able to attenuate infection in the murine model of
UTI and potentiate efficacy of standard antibiotics, likely by limiting UPEC to a luminal niche
where antibiotic concentrations are high (163). Further, compounds inhibiting UPEC pilus
biosynthesis (pilicides) by selectively inhibiting either the type P or type 1 chaperones, PapD and
FimC, represent another class of rationally designed anti-virulence compounds (164). Pilicide
treatment of UPEC abrogates pili formation, without effect on assembled pili, and pretreatment
attenuates virulence in mice, suggesting the pilicides may exemplify another promising lead for
future anti-virulence therapy (164-166). Additionally, compounds interfering with the regulatory
processes governing urovirulence determinants may provide a fertile area for future therapeutics
(167, 168). Collectively, these results point to a promising future for development of antivirulence therapy against UTI.
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Vaccine prospects
With the rise in antibiotic resistance among uropathogens and the frequency with which
many women suffer repeated UTIs despite antibiotic treatment, there has also been significant
effort invested into the development of vaccines against UPEC. A recent review provides
comprehensive documentation of all the evidence-based and clinical investigations that focus on
vaccine development against UTIs (169). A notable challenge in the field is that although the
goal is to eradicate UPEC from the urinary tract, E. coli represents an important component of
the gastrointestinal microflora. As such, it would be disadvantageous for any antimicrobial
approach to eradicate these commensal forms of E. coli. This concern has led investigators to
target proteins that are specifically associated with pathogenic strains in an attempt to leave the
gastrointestinal flora unperturbed. To date, approaches have included multivalent whole-cellbased cocktails or candidate preparations of individual bacterial components.

Individual bacterial components.
As binding to uroepithelial surfaces is critical for the establishment of UTI, many vaccine
candidates are directed against microbial surface structures that would directly or indirectly
affect bacterial binding. Uropathogenic strains of E. coli are quite heterogeneous in genetic
content (51). Surface-expressed molecules that define E. coli serotypes might serve as potential
immunogens, but these molecules are very heterogeneous among strains isolated from the
urinary tract. For example, there are as many as twenty LPS O-antigen serotypes, just one
example of the potential diversity in surface molecules among E. coli strains that cause UTI.
Other classes of vaccine targets that have been investigated include adhesive organelles,
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exotoxins, iron receptors, flagella, and capsule (169). These targets have demonstrated efficacy
in animal models, but few have been taken forward to any form of clinical trial.

Multivalent approaches.
These strategies include the use of bacterial proteins in the form of bacterial lysates (UroVaxom®) (170) or intact bacteria (Urovac®, Urvakol®) (171, 172), which offers the advantage
of inclusion of a large number of potential immunogens. In fact, numerous E. coli serotypes
could be included in such a cocktail to broaden potential efficacy against diverse E. coli strains.
However, there are a number of potential limitations to this approach. First, the growth
conditions of the organisms during preparation must approximate those within the urinary tract
to encourage production of UTI-relevant molecules. Second, this approach would include
molecules that are also common to commensal E. coli. Immunostimulation against such
common E. coli molecules could lead to reduced levels of E. coli in the gastrointestinal tract,
which could compromise gastrointestinal microbiome integrity, or even elicit unintended
gastrointestinal inflammation. Lastly, the presence of a plethora of microbial proteins could
reduce the immunogenicity toward any one important target and, as such, the efficacy of
vaccination may be adversely affected. Of note, these polyvalent approaches have demonstrated
efficacy in the prevention of UTI in animal and human studies (170-172). However, there have
been adverse side effects at the delivery site, or a need for repetitive administration in order to
attain prolonged efficacy, reducing the enthusiasm for the use of these vaccines.
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Conclusion
Recent years have seen a remarkable increase in our understanding of the virulence
attributes and behavior of uropathogenic E. coli in the urinary tract. New paradigms raise the
possibility that recurrent urinary tract infections may arise via mechanisms other than
reinoculation from a gastrointestinal tract reservoir. This new knowledge, as well as the
molecular details of pilus assembly, bacterial attachment and epithelial invasion, opens new
avenues for development of anti-virulence compounds and strategies. Coupled with renewed
interest in vaccine targets for UTI, these approaches are expected to be increasingly important as
antimicrobial resistance among UPEC and other uropathogenic bacteria becomes more
widespread.
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Figures

Figure 1. The intracellular bacterial community model of bacterial cystitis. Infection
begins with bacterial attachment to the uroepithelium (A), followed shortly by internalization
into superficial epithelial cells (B). A subset of UPEC gains access to the cytoplasm, replicating
into IBCs (C, D). Ultimately UPEC flux from the infected cell, some organisms adopting a
filamentous morphology (E) to initiate subsequent rounds of IBC formation. Outcomes of the
acute phase of infection include the formation of quiescent intracellular reservoirs (QIRs; F) or,
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in susceptible hosts, the development of chronic active cystitis (G). Reproduced with permission
from Reference 105.
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Table 1. Host factors influencing bacterial adherence and invasion
Attachment
Actin
cAMP
Caveolae
Histone deacetylase
Integrin
Lipid rafts
Microtubules
MyRIP
Rab27b
Rho-GTPase
TLR4
Uroplakin Ia
Uroplakin IIIa

Invasion
(14, 17)
(11)
(12)
(173)
(16)
(12)
(173)

(16)

(11)
(17)
(113)
(26)

Expulsion / Blocking
(14)
(11, 113)
(113)
(173)

(173)
(113)
(113)
(113)

(93)
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(93)
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Abstract
Uropathogenic Escherichia coli (UPEC) cause the majority of community-onset urinary tract
infection (UTI) and represent a major etiologic agent of healthcare-associated UTI. Introduction
of UPEC into the mammalian urinary tract evokes a well-described inflammatory response,
comprising pro-inflammatory cytokines and chemokines as well as cellular elements (neutrophils
and macrophages). In human UTI, this inflammatory response contributes to symptomatology
and provides means for diagnosis by standard clinical testing. Early in acute cystitis, UPEC
gains access to an intracellular niche that protects a population of replicating bacteria from
arriving phagocytes. To ensure the establishment of this protected niche, UPEC employ multiple
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strategies to attenuate and delay the initiation of host inflammatory components, including
epithelial secretion of chemoattractants. Recent work has also revealed novel mechanisms by
which UPEC blunts neutrophil migration across infected uroepithelium. Taken together, these
attributes distinguish UPEC from commensal and nonpathogenic E. coli strains. This review
highlights the unique immune evasion and suppression strategies of this bacterial pathogen and
offers directions for further study; molecular understanding of these mechanisms will inform the
development of adjunctive, anti-virulence therapeutics for UTI.

Introduction
The human immune system faces a constant obligation to provide surveillance at
epithelial surfaces and to detect and eliminate pathogenic microbes. Innate responses are
triggered by ligation of pathogen-recognition receptors on and within epithelial cells and resident
immune cells. These responses activate and recruit phagocytes, particularly macrophages and
neutrophils (polymorphonuclear leukocytes; PMNs), which act to engulf and kill bacterial
pathogens at the point of their arrival. Conversely, in order to establish infection and thwart
immune detection and clearance, microorganisms of all types have evolved a variety of
molecular mechanisms to attenuate and evade mammalian innate immunity (reviewed in [1-4]
among many others). Even among Gram-negative bacteria, the mechanisms of these effects vary
widely. In many model pathogens (e.g., Salmonella, Vibrio, Yersinia), effector proteins
interrupting host cell signaling, kinase activation, cytoskeletal rearrangement, post-translational
modification, and other processes are delivered to the target cell via type III secretion. Here, we
will outline the distinct immune modulation strategies of uropathogenic Escherichia coli
(UPEC), the chief cause of urinary tract infections [5,6]. Unlike other pathotypes of E. coli that
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modulate host responses (e.g., enterohemorrhagic or enteropathogenic), UPEC do not encode
type III secretion machinery.
The ascending introduction of UPEC or other pathogenic bacteria into the mammalian
urinary tract induces an inflammatory response, initiated primarily by activation of Toll-like
receptors (TLRs). Stimulation of TLR4 by bacterial lipopolysaccharide (LPS) activates the NFκB pathway, inducing the expression of cytokines including IL-6 and neutrophil
chemoattractants such as IL-8 (CXCL1), which are measurable in the urine of mice and humans
with UTI [7,8]. Increases in uroepithelial cyclic AMP, activated by TLR4-induced increases in
intracellular [Ca2+], also results in NF-κB-independent augmentation of IL-6 and IL-8 expression
[9]. TLR5 stimulation, responding to bacterial flagellin, can additionally contribute to acute
inflammation during UTI [10,11]. Perpetuation of the neutrophil response may be driven by
cytokines such as IL-17, which has an emerging role in bridging innate to adaptive immunity
[12] and is a mediator of the innate response during experimental UTI [13]. The human
cathelicidin LL-37, a small, cationic antibacterial peptide, is detectable in the urine during human
cystitis, and mice deficient in its ortholog (CRAMP) demonstrate increased susceptibility to
pyelonephritis [14], although it may paradoxically enhance bladder infection [15]. Multiple
members of the defensin class of antimicrobial peptides are also produced locally during UTI,
and the participation of these molecules in the host-pathogen conversation remains a fertile area
for study.
A core result of the soluble inflammatory response is the recruitment of neutrophils to the
bladder. Indeed, the detection of neutrophils in the urine is a diagnostic hallmark of human UTI.
The phagocytic capacity of neutrophils plays a critical role in controlling UPEC UTI, as
demonstrated in multiple studies [16-21]. UPEC is able to effectively colonize the bladder in the
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face of this highly inflammatory soluble and cellular response, first attenuating phagocyte
recruitment and subsequently evading the activity of neutrophils in the bladder. The molecular
strategies underlying these UPEC phenotypes are the focus of this review.

Immune evasion strategies of UPEC
The UPEC intracellular bacterial community.
As detailed elsewhere in this issue, acute UPEC cystitis relies on a well-documented
intracellular pathogenesis cascade in which the pathogen is internalized into superficial bladder
epithelial cells (also termed facet or umbrella cells) [22-33]. Despite comprising a minority of
total bacteria within the infected bladder (most are luminal), intracellular UPEC coordinate a
variety of essential functions to propagate infection. The facet cell cytoplasm provides a rich
nutrient environment that supports the massive intracellular replication of UPEC in the acute
phase of cystitis, forming the intracellular bacterial community (IBC) [28]. However, this locale
also represents a vitally important, protected niche whereby UPEC can evade the phagocytic
activity of arriving neutrophils. By video microscopy in the infected murine bladder, neutrophils
can be observed engulfing luminal bacilli during the initial hours of infection [34]. However,
bacteria that have successfully invaded uroepithelial cells are sheltered from this attack;
neutrophils are clearly able to locate infected epithelial cells, but cannot access the expanding
bacterial population comprising the IBC (Figure 1). As part of the host response to infection,
many of the facet cells will ultimately be exfoliated into the urine – a means by which the host
may rid itself of many thousands of bacteria. In order to escape this fate and perpetuate
infection, a subset of UPEC must exit the IBC and initiate additional genetic programs that allow
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these bacteria to traverse the extracellular space in the face of a burgeoning luminal neutrophil
population, thereby facilitating additional rounds of IBC formation in naïve epithelial cells.

Filamentation.
During maturation of the IBC, a minority of the intracellular population proceeds through a
differentiation pathway that results in the formation of non-septated, filamentous bacteria up to
70 μm in length – a process that requires expression of the cell division inhibitor SulA [34,35].
Upon lysis of the IBC-harboring facet cell, UPEC flux out of the IBC proper to traverse the
luminal surface. Video microscopy demonstrates that during this time of transition, bacillary
forms of UPEC (1-2 μm in length) are readily engulfed, while filamentous UPEC resist
phagocytosis, even when in direct contact with PMNs and macrophages [35,36] (Figure 2). At
this juncture during murine cystitis, flow cytometric analysis of bladder luminal bacteria
demonstrates enrichment of filamentous forms, consistent with a selection process in which
bacillary forms are preferentially taken up by host phagocytes [34]. This preferential engulfment
of standard bacilli is also supported by in vitro studies using cultured bladder epithelial cells and
human macrophages [34,36]. As PMNs are in fact capable of engulfing particles (e.g., fungal
hyphae) that are larger than themselves [37,38], the observed resistance of filamentous UPEC to
PMN phagocytosis likely relies on attributes beyond the organism’s size [35]. Underscoring the
pathogenic importance of filamentation, the UPEC sulA mutant forms a first round of IBCs
without difficulty, but fails to sustain infection beyond this point, as it cannot filament in order to
survive the luminal transition. Abrogation of the PMN response (e.g., in TLR4-deficient mice)
rescues the sulA pathogenic defect [35].
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The adoption of the filamentous phenotype by a subset of UPEC represents a response of
the pathogen to stresses associated with the marshaling of host immune components. In support
of this model, filamentation is not observed during UPEC UTI in TLR4-deficient hosts, which
feature a sharply limited soluble and cellular inflammatory response to bacterial introduction.
Meanwhile, filamentation can be induced in vitro by exposure of bacillary UPEC to LPSactivated macrophages [34,36]. Taken together, these observations demonstrate an elegant hostpathogen conversation taking place during this critical stage of UTI propagation.

UPEC attenuation of early uroepithelial cytokine production.
While the full extent of the neutrophilic response to bacterial cystitis is fully evident within
hours, internalization of UPEC into bladder epithelial cells occurs initially in < 1 h [28,39].
Substantial work by multiple groups has outlined a number of pathogenic strategies by which
UPEC may dampen very early innate responses, effectively “holding off the cavalry” to protect
luminal bacteria until the protected intracellular niche can be established.
Compared with commensal or laboratory strains of E. coli, UPEC display a marked ability to
dominantly suppress epithelial cytokine production. UPEC stabilize IκB, thereby suppressing
NF-κB activity and increasing bladder epithelial cell apoptosis [40]. Further, multiple UPEC
isolates elicit lower levels of IL-6 and IL-8 from uroepithelial cells and are able to block
secretion of these inflammatory cytokines upon co-inoculation with known NF-κB stimulators
[41,42]. Genes involved in LPS biosynthesis (e.g., rfa, rfb, waaL) are also important for this
phenotype, suggesting that UPEC LPS modifications may at least confer a less stimulatory LPS
structure, or perhaps that a non-stimulatory LPS may exert a dominant effect [42,43]. In
addition, lack of the OMP chaperone SurA abolishes the immunosuppressive phenotype [42];
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reduced levels of the SurA-dependent LPS transport protein LptD may alter the presentation of
potentially non-stimulatory LPS [44].
However, LPS differences alone do not account for cytokine suppression [45], and it is likely
that other mechanisms and UPEC effectors also contribute to suppressing cytokine secretion.
For example, NF-κB signaling may be inhibited by sub-lytic concentrations of α-hemolysin
(HlyA) [46,47], which is encoded on a UPEC pathogenicity island that also harbors Cnf1 (see
section 2.4). Exemplifying a distinct strategy, a substantial minority of UPEC isolates, including
the pyelonephritis/urosepsis strain CFT073, encode a Toll/IL-1 receptor (TIR) domaincontaining protein, termed TcpC, that interacts with the host adaptor MyD88 to inhibit TLR
signaling [48]. TcpC disruption was associated with decreased bacterial burden in the kidneys
and a reduction in histologically evident renal damage, indicating the importance of this protein
during pyelonephritis. Further study of additional signaling pathways that rely on TIR domaincontaining proteins (e.g., the TRIF and IL-6/IL-1 signaling cascades) revealed that TcpC also
regulated these pathways independent of MyD88, suggesting that TcpC may impact pathogenesis
in a broader way [49]. Finally, the SisA and SisB proteins, homologues of the
immunomodulatory protein ShiA from Shigella flexneri, are found in CFT073 and have recently
been implicated in immune modulation during UTI [50].

UPEC inhibition of neutrophil recruitment and function
Uropathogenic strains of E. coli feature additional virulence mechanisms targeting the
recruitment and function of neutrophils. In contrast to commensal and laboratory E. coli isolates,
UPEC are able to suppress neutrophil migration by down-regulating expression of many PMN
genes involved in neutrophil chemotaxis, proinflammatory signaling, adhesion, and migration
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[51]. To study the molecular determinants of this phenomenon, we recently optimized an in
vitro model of PMN migration across a cultured bladder epithelial cell monolayer [51-53].
UPEC isolates both attenuate transepithelial PMN migration in vitro and elicit reduced bladder
PMN influx in vivo, in contrast to nonpathogenic strains [51,53].
UPEC have been shown to induce a number of anti-inflammatory molecules within PMNs
and uroepithelial cells, including indoleamine 2,3-dioxygenase (IDO) [51]. IDO represents the
first enzyme in the catabolism of tryptophan and is well known to modulate adaptive immunity,
specifically T cell functions, by starving the local milieu of tryptophan [54]. Unlike
nonpathogenic E. coli, UPEC specifically upregulate IDO locally within 1 h after introduction
into the murine bladder, resulting in attenuation of innate cellular responses (i.e., neutrophil
recruitment). Compared with wild-type hosts, UTI in IDO-deficient mice features augmented
PMN migration, corresponding with increased killing of extracellular (luminal) bacteria and
attenuation of infection [55]. Though the key IDO-expressing cell types have not yet been
specified, contributions from both the epithelial and hematopoietic compartments are being
investigated. Independent of this question, the sequential influence of two canonical IDO
stimulators, namely TNFα and interferons (both type I and IFNγ), appears to underlie UPEC
induction of IDO in the host ([55] and unpublished data). Notably, IDO influence on PMN
migration is not mediated via tryptophan starvation, as experimental addition of exogenous
tryptophan does not rescue neutrophil migration. Instead, the products of tryptophan catabolism,
known collectively as kynurenines, may exert a direct influence on PMN transuroepithelial
migration.
UPEC also employ a variety of secreted toxins and effectors to neutralize the phagocytic
activity of PMNs. As noted above, α-hemolysin (HlyA) is cytolytic to hematopoietic cells but
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also has subtler immune-modulating effects at sub-lytic concentrations [56,57]. The genetically
linked UPEC toxin termed cytotoxic necrotizing factor 1 (CNF1) suppresses PMN chemotaxis,
phagocytic activity and release of reactive oxygen species [58,59]. Interestingly, CNF1 appears
to be packaged into outer membrane vesicles, structures liberated by all Gram-negative bacteria,
for delivery to the target phagocyte [59]. A newly identified UPEC effector, termed YbcL, has
been shown to inhibit transepithelial migration of human neutrophils in vivo and in vitro via a
mechanism that is distinct but as yet incompletely defined. This effector localizes initially to the
bacterial periplasm and is subsequently liberated via bacterial lysis, suppressing PMN
transepithelial migration in both in vivo and in vitro model systems [53,60]. YbcL homologs are
present in laboratory and commensal E. coli isolates but are unable to suppress PMN migration
due to a single amino acid alteration, while most UPEC strains encode the suppressive YbcL
variant [53]. Interestingly, YbcL suppression of PMN migration requires the presence of
uroepithelial cells (i.e., it does not act directly on PMN alone), and the bacterial lysis that
liberates YbcL is augmented by bacterial exposure to bladder epithelia [60]. These observations
highlight a form of bacterial altruism in which a subset of UPEC arriving in the mammalian
bladder are sacrificed such that others in the nascent UPEC community may achieve success in
colonizing the bladder epithelium.

Does inflammation ultimately promote UPEC infection?
A recent body of literature supports a model in which host inflammation during UTI may
actually represent a double-edged sword. As has been discussed, the acute inflammatory
response is essential for controlling UTI [17,61,62]; however, overly exuberant inflammatory
responses during acute cystitis may be associated with increased tissue damage, predisposing the
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host to developing chronic forms of infection [63,64]. In susceptible murine hosts (e.g.,
C3H/HeN), a fraction of mice are unable to resolve acute UTI, developing long-term chronic
bacterial cystitis with ongoing high tissue bacterial burden and inflammation. This appears to
arise as the result of an early immune checkpoint, which can be altered experimentally by prior
treatment with anti-inflammatory agents, subsequently preventing chronic infection [63,65].
Further, after chronic cystitis has become established, hosts are unable to resolve infection
despite an intense, ongoing leukocyte response, and restoration of the exfoliated transitional
epithelium is inhibited [63]. This inflamed state may thus allow UPEC access to more protected
niches and deeper cell layers. Thus, hosts need to mount a finely tuned inflammatory response in
order to eliminate uropathogens while avoiding the detrimental consequences of an exaggerated
response that may augment disease severity or promote persistent infection.

Conclusions and Future Directions
Our knowledge of acute immunity during UTI and the mechanisms that UPEC exploit to
evade it has increased dramatically over the past decade. Ongoing work aims to establish the
molecular mechanisms of recently published immune evasion effectors and strategies. For
example, previous studies suggest that YbcL has greatest structural homology to the mammalian
Raf kinase inhibitory protein and may therefore interact with eukaryotic kinases [66]; specifying
putative binding partners and targets within a host cell may elucidate the mechanism of this
novel PMN trafficking inhibitor. In the same light, we are investigating how kynurenines
produced by IDO tryptophan catabolism influence neutrophil migration. These studies will
further illuminate the complex host-pathogen interactions occurring in the very early stages of
UTI establishment.
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Similarly, our understanding of protective immunity and the predictors of recurrent UTI is
incomplete. Multiple groups are continuing work on the humoral immune response to cystitis
and pyelonephritis and identification of immunodominant antigens. As well, studies of adaptive
cellular responses with correlation to recurrence risk should be prioritized. In the decade to
come, it is hoped that such investigations will enable novel approaches to limit the morbidity of
these recalcitrant infections.
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Figures

Figure 1. Intracellular UPEC communities are protected from neutrophil attack.
Confocal microscopy during acute murine cystitis, viewed from a luminal perspective,
shows an intracellular bacterial community of UPEC (yellow) within a binucleate
superficial facet cell that is surrounded by recruited neutrophils (revealed by red nuclear
staining; larger, round epithelial cell nuclei are also visible).
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Figure 2. Filamentous UPEC resist phagocytosis in the bladder. Confocal microscopy
shows a (luminal) surface collection of bacillary and filamentous UPEC (green) in which
the bacterial filaments are heavily intermingled with neutrophils (red nuclei). Scale bar, 10
μm.
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